Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Efficacy, Safety, Tolerability and Pharmacokinetics of Tofacitinib for Treatment of Systemic Juvenile Idiopathic Arthritis (sJIA) With Active Systemic Features in Children and Adolescent Subjects

    Summary
    EudraCT number
    2017-002018-29
    Trial protocol
    SK   PL   DE   BE   IT   NL   SE   HU  
    Global end of trial date
    27 Mar 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    10 Oct 2024
    First version publication date
    10 Oct 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    A3921165
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03000439
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Pfizer Inc.
    Sponsor organisation address
    235 E 42nd Street, New York, United States, NY 10017
    Public contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Scientific contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-000576-PIP01-09
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    24 Jul 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Mar 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the sustained efficacy of tofacitinib versus placebo in sJIA participants, as measured by time to sJIA flare in the double-blind randomized withdrawal phase.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    10 May 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 2
    Country: Number of subjects enrolled
    Belgium: 1
    Country: Number of subjects enrolled
    Brazil: 3
    Country: Number of subjects enrolled
    Canada: 2
    Country: Number of subjects enrolled
    China: 26
    Country: Number of subjects enrolled
    Germany: 1
    Country: Number of subjects enrolled
    India: 22
    Country: Number of subjects enrolled
    Israel: 7
    Country: Number of subjects enrolled
    Italy: 1
    Country: Number of subjects enrolled
    Mexico: 4
    Country: Number of subjects enrolled
    Poland: 1
    Country: Number of subjects enrolled
    Russian Federation: 3
    Country: Number of subjects enrolled
    South Africa: 9
    Country: Number of subjects enrolled
    Spain: 4
    Country: Number of subjects enrolled
    Türkiye: 1
    Country: Number of subjects enrolled
    Ukraine: 7
    Country: Number of subjects enrolled
    United States: 6
    Worldwide total number of subjects
    100
    EEA total number of subjects
    8
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    60
    Adolescents (12-17 years)
    40
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Details participants who were diagnosed with Systemic Juvenile Idiopathic Arthritis (sJIA) with active systemic features were enrolled.

    Pre-assignment
    Screening details
    A total of 168 participants were screened, of which 68 failed screening and only 100 participants were enrolled in open label part 1 (OLP1). From the total of 100 participants enrolled into OLP1 of the study, 54 participants were treated in open label part 2 (OLP2), and 59 participants were randomised between the treatment groups in the DB phase.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Subject
    Blinding implementation details
    OL Part 1 and Part 2 was open label and allocation was not applicable

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Arm description
    Participants were administered tofacitinib 5 milligram (mg) twice a day (BID) via the oral route and continued to receive a stable dose of corticosteroids (Cs) during open label part 1.
    Arm type
    Experimental

    Investigational medicinal product name
    Tofacitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Oral solution, Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Tofacitinib 5 mg was administered as an oral tablet BID for participants greater than equal to (>=) 40 kilograms (kg) and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants less than (<) 40 kg.

    Arm title
    Tofacitinib 5mg BID OL Part 2
    Arm description
    Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with ˃0.2 milligram/kilogram/day (mg/kg/day) oral prednisone (or equivalent).
    Arm type
    Experimental

    Investigational medicinal product name
    Tofacitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Tofacitinib 5 mg was administered as an oral tablet BID for participants >=40 kg and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants <40 kg.

    Arm title
    Tofacitinib 5mg BID Double-Blind (DB)
    Arm description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.
    Arm type
    Experimental

    Investigational medicinal product name
    Tofacitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Tofacitinib 5 mg was administered as an oral tablet BID for participants >=40 kg and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants <40 kg.

    Arm title
    Placebo DB
    Arm description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo of tofacitinib 5 mg was administered as an oral tablet BID for participants >=40 kg and as an equivalent weight-based lower dose of tofacitinib oral solution (1 mg/mL) BID for participants <40 kg.

    Number of subjects in period 1
    Tofacitinib 5mg BID Open_Label (OL) Part 1 Tofacitinib 5mg BID OL Part 2 Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Started
    100
    54
    28
    31
    Completed
    76
    37
    14
    17
    Not completed
    24
    17
    14
    14
         Adverse event, non-fatal
    2
    -
    2
    -
         Adverse event, serious non-fatal
    4
    -
    -
    1
         Unspecified
    2
    5
    10
    11
         Withdrawal by parent/guardian
    -
    -
    2
    -
         Insufficient clinical response
    16
    12
    -
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Reporting group description
    Participants were administered tofacitinib 5 milligram (mg) twice a day (BID) via the oral route and continued to receive a stable dose of corticosteroids (Cs) during open label part 1.

    Reporting group title
    Tofacitinib 5mg BID OL Part 2
    Reporting group description
    Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with ˃0.2 milligram/kilogram/day (mg/kg/day) oral prednisone (or equivalent).

    Reporting group title
    Tofacitinib 5mg BID Double-Blind (DB)
    Reporting group description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.

    Reporting group title
    Placebo DB
    Reporting group description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.

    Reporting group values
    Tofacitinib 5mg BID Open_Label (OL) Part 1 Tofacitinib 5mg BID OL Part 2 Tofacitinib 5mg BID Double-Blind (DB) Placebo DB Total
    Number of subjects
    100 54 28 31 213
    Age Categorical
    A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.
    Units: Participants
        2 to < 6 Years
    17 10 3 6 36
        6 to < 12 Years
    43 21 12 11 87
        12 to < 18 Years
    40 23 13 14 90
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    9.97 ( 4.11 ) 9.85 ( 4.33 ) 10.36 ( 4.34 ) 10.35 ( 4.55 ) -
    Gender categorical
    A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.
    Units: Participants
        Male
    56 33 16 22 127
        Female
    44 21 12 9 86
    Ethnicity
    A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.
    Units: Subjects
        Hispanic or Latino
    14 11 3 4 32
        Not Hispanic or Latino
    86 43 25 27 181
    Race
    A total of 100 participants were enrolled into the study. From the total of 100 participants enrolled into the OL part 1 of the study. 54 participants entered in OL part 2. From OL phase, 59 participants were randomised between the treatment group in the DB phase. The number of participants in total column are not presenting actual enrolled participants.
    Units: Subjects
        White
    39 23 11 13 86
        Black or African American
    7 4 3 2 16
        Asian
    49 23 13 14 99
        Other
    5 4 1 2 12

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Reporting group description
    Participants were administered tofacitinib 5 milligram (mg) twice a day (BID) via the oral route and continued to receive a stable dose of corticosteroids (Cs) during open label part 1.

    Reporting group title
    Tofacitinib 5mg BID OL Part 2
    Reporting group description
    Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with ˃0.2 milligram/kilogram/day (mg/kg/day) oral prednisone (or equivalent).

    Reporting group title
    Tofacitinib 5mg BID Double-Blind (DB)
    Reporting group description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.

    Reporting group title
    Placebo DB
    Reporting group description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.

    Primary: Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase

    Close Top of page
    End point title
    Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase [1]
    End point description
    Time to the disease flare=the number of days from randomisation to flare in the DB phase and calculated as date of disease flare=date of randomization plus (+)1. sJIA Flare=as at least one of the following criteria:Recurrence of fever (>38 degree Celsius/100.4-degree Fahrenheit) on 2 or more consecutive days) was considered due to SJIA activity.Worsening of 30 percent (%) or more in three or more of the six variables included: Number of joints with active arthritis and limited range of motion, disease activity, Parent child evaluation of overall well-being,functional ability (Disability Index), erythrocyte sedimentation rate (ESR), of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomisation into the withdrawal phase. 95% Confidence Interval (CI) based on Brookmeyer and Crowley Method. Double-Blind Full Analysis Set was used. 99999 indicates data could not be calculated due to less number of participants with events.
    End point type
    Primary
    End point timeframe
    From randomization to up to 248 weeks
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Days
        median (confidence interval 95%)
    99999 (186.0 to 99999)
    295.0 (99.0 to 99999)
    Statistical analysis title
    Tofacitinib 5mg BID DB, Placebo DB
    Statistical analysis description
    Hazard ratio and 95% CI was based on Cox proportional hazards model with treatment group as covariate.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.1171
    Method
    Unstratified log-rank test
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.633
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.296
         upper limit
    1.354

    Secondary: Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase

    Close Top of page
    End point title
    Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase [2]
    End point description
    sJIA Flare was defined as at least one of the following criteria: recurrence of fever (>38° C/100.4° F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30% or more in three or more of the six variables: number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability (CHAQ Disability Index), ESR. of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomisation into the withdrawal phase. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Probability of event
    number (not applicable)
        DB Week 4
    7.1
    6.5
        DB Week 8
    14.3
    22.6
        DB Week 12
    21.4
    32.3
        DB Week 16
    25.0
    38.7
        DB Week 20
    32.1
    45.4
        DB Week 24
    32.1
    45.4
        DB Week 28
    35.9
    45.4
        DB Week 32
    35.9
    49.9
        DB Week 36
    40.5
    49.9
        DB Week 40
    40.5
    49.9
        DB Week 44
    40.5
    55.5
        DB Week 48
    40.5
    55.5
        DB Week 52
    40.5
    55.5
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [3]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.2
         upper limit
    13.6
    Notes
    [3] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [4]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -10.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -33.2
         upper limit
    11.6
    Notes
    [4] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [5]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -13.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -37.2
         upper limit
    9.8
    Notes
    [5] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [6]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -13.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -37.9
         upper limit
    11.5
    Notes
    [6] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [7]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -13.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -37.9
         upper limit
    11.5
    Notes
    [7] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [8]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.9
         upper limit
    11.3
    Notes
    [8] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [9]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -9.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -34.5
         upper limit
    15.6
    Notes
    [9] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [10]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -41.8
         upper limit
    11.8
    Notes
    [10] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [11]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -39.5
         upper limit
    11.5
    Notes
    [11] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [12]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -9.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -35.5
         upper limit
    16.7
    Notes
    [12] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [13]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -9.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -35.5
         upper limit
    16.7
    Notes
    [13] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [14]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -41.8
         upper limit
    11.8
    Notes
    [14] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [15]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -41.8
         upper limit
    11.8
    Notes
    [15] - The 95% CIs for the differences between the treatment groups were generated using Greenwood’s formula.

    Secondary: Percentage of Participants who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2 [16]
    End point description
    A successfully tapered participant was considered as the one that completed part 2 of the OL by reaching their target corticosteroid dose and maintained an adapted JIA American College of Rheumatology (ACR) 30 response for four weeks on this dose. The target CS dose at the end of part 2 included <=0.5 mg/kg/day up to a maximum dose of 15 mg/day oral prednisone (or equivalent) for CS˃0.8 mg/kg/day oral prednisone; reduction to <=0.3 mg/kg/day up to a maximum of 12 mg/day oral prednisone (or equivalent) for CS <=0.8 mg/kg/day->=0.5 mg/kg/day oral prednisone (or equivalent) and <=0.2 mg/kg/day up to a maximum dose of 10 mg/day oral prednisone (or equivalent) for CS <0.5 mg/kg/day-CS˃0.2 mg/kg/day oral prednisone (or equivalent). 95% CI was based on normal approximation. Open-label part 2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2.
    End point type
    Secondary
    End point timeframe
    From end of OL Part 1 to up to 24 weeks in OL Part 2
    Notes
    [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
        number (confidence interval 95%)
    70.37 (58.19 to 82.55)
    No statistical analyses for this end point

    Secondary: Percentage of Participants who Achieved Corticosteroid Dose of Less Than or Equal to (<=) 0.2 mg/kg/day or 10 mg/day: at the End of Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants who Achieved Corticosteroid Dose of Less Than or Equal to (<=) 0.2 mg/kg/day or 10 mg/day: at the End of Open-label Phase Part 2 [17]
    End point description
    95% CI was based on normal approximation. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2.
    End point type
    Secondary
    End point timeframe
    From end of OL Part 1 to up to 24 weeks in OL Part 2
    Notes
    [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
        number (confidence interval 95%)
    59.26 (46.15 to 72.36)
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    Close Top of page
    End point title
    Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase [18]
    End point description
    Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of >=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by >=30%. Variables included: number of joints with active arthritis (any joint with swelling, or in absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on a visual analog scale (VAS) from 0=no disease activity to 100=very severe disease activity; Parent/ legal guardian/Child evaluation of overall well-being on VAS from 0= very well to 100 millimeter (mm)= very poor; functional ability (Disability Index) ESR. DBFAS set was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of participants
    number (not applicable)
        ACR30:DB Week 4
    82.14
    93.55
        ACR30:DB Week 8
    82.14
    80.65
        ACR30:DB Week 12
    71.43
    70.97
        ACR30:DB Week 16
    71.43
    61.29
        ACR30:DB Week 20
    67.86
    51.61
        ACR30:DB Week 24
    64.29
    54.84
        ACR30:DB Week 28
    60.71
    51.61
        ACR30:DB Week 32
    60.71
    51.61
        ACR30:DB Week 36
    60.71
    51.61
        ACR30:DB Week 40
    60.71
    51.61
        ACR30:DB Week 44
    60.71
    51.61
        ACR30:DB Week 48
    60.71
    48.39
        ACR30:DB Week 52
    60.71
    48.39
        ACR50:DB Week 4
    82.14
    93.55
        ACR50:DB Week 8
    82.14
    77.42
        ACR50:DB Week 12
    71.43
    70.97
        ACR50:DB Week 16
    71.43
    58.06
        ACR50:DB Week 20
    67.86
    48.39
        ACR50:DB Week 24
    64.29
    54.84
        ACR50:DB Week 28
    60.71
    51.61
        ACR50:DB Week 32
    60.71
    51.61
        ACR50:DB Week 36
    60.71
    51.61
        ACR50:DB Week 40
    60.71
    51.61
        ACR50:DB Week 44
    60.71
    48.39
        ACR50:DB Week 48
    60.71
    48.39
        ACR50:DB Week 52
    60.71
    48.39
        ACR70:DB Week 4
    57.14
    70.97
        ACR70:DB Week 8
    67.86
    77.42
        ACR70:DB Week 12
    64.29
    64.52
        ACR70:DB Week 16
    60.71
    54.84
        ACR70:DB Week 20
    64.29
    45.16
        ACR70:DB Week 24
    53.57
    51.61
        ACR70:DB Week 28
    57.14
    41.94
        ACR70:DB Week 32
    60.71
    48.39
        ACR70:DB Week 36
    60.71
    51.61
        ACR70:DB Week 40
    60.71
    48.39
        ACR70:DB Week 44
    60.71
    48.39
        ACR70:DB Week 48
    60.71
    48.39
        ACR70:DB Week 52
    60.71
    48.39
        ACR90:DB Week 4
    28.57
    48.39
        ACR90:DB Week 8
    21.43
    38.71
        ACR90:DB Week 12
    25.00
    38.71
        ACR90:DB Week 16
    25.00
    29.03
        ACR90:DB Week 20
    21.43
    29.03
        ACR90:DB Week 24
    21.43
    25.81
        ACR90:DB Week 28
    17.86
    25.81
        ACR90:DB Week 32
    14.29
    29.03
        ACR90:DB Week 36
    28.57
    35.48
        ACR90:DB Week 40
    28.57
    32.26
        ACR90:DB Week 44
    28.57
    29.03
        ACR90:DB Week 48
    28.57
    29.03
        ACR90:DB Week 52
    28.57
    29.03
        ACR100:DB Week 4
    14.29
    35.48
        ACR100:DB Week 8
    10.71
    29.03
        ACR100:DB Week 12
    14.29
    25.81
        ACR100:DB Week 16
    17.86
    25.81
        ACR100:DB Week 20
    14.29
    12.90
        ACR100:DB Week 24
    17.86
    19.35
        ACR100:DB Week 28
    14.29
    22.58
        ACR100:DB Week 32
    10.71
    25.81
        ACR100:DB Week 36
    14.29
    25.81
        ACR100:DB Week 40
    21.43
    29.03
        ACR100:DB Week 44
    21.43
    25.81
        ACR100:DB Week 48
    25.00
    25.81
        ACR100:DB Week 52
    25.00
    25.81
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [19]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.41
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -28.02
         upper limit
    5.21
    Notes
    [19] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [20]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    1.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -18.37
         upper limit
    21.36
    Notes
    [20] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [21]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [21] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [22]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [22] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [23]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [23] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [24]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [24] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [25]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [25] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [26]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [26] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [27]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.49
         upper limit
    34.39
    Notes
    [27] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [28]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    16.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -8.43
         upper limit
    40.92
    Notes
    [28] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [29]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    10.14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.82
         upper limit
    34.1
    Notes
    [29] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [30]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -22.68
         upper limit
    23.6
    Notes
    [30] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [31]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [31] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [32]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [32] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [33]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [33] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [34]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [34] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [35]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.49
         upper limit
    34.39
    Notes
    [35] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [36]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [36] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [37]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    13.36
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -10.76
         upper limit
    37.48
    Notes
    [37] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [38]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -22.68
         upper limit
    23.6
    Notes
    [38] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [39]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    4.72
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.72
         upper limit
    25.17
    Notes
    [39] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [40]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.41
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -28.02
         upper limit
    5.21
    Notes
    [40] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [41]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    19.47
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.2
         upper limit
    44.14
    Notes
    [41] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [42]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [42] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR50: DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [43]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [43] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [44]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -13.82
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -38.14
         upper limit
    10.49
    Notes
    [44] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [45]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -9.56
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -32.28
         upper limit
    13.15
    Notes
    [45] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [46]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.7
         upper limit
    24.24
    Notes
    [46] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [47]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    5.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -19.31
         upper limit
    31.06
    Notes
    [47] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [48]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    19.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.81
         upper limit
    44.06
    Notes
    [48] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [49]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    1.96
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.55
         upper limit
    27.47
    Notes
    [49] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [50]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    15.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -10.05
         upper limit
    40.46
    Notes
    [50] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [51]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [51] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [52]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [52] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [53]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -19.82
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -44.09
         upper limit
    4.46
    Notes
    [53] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [54]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [54] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [55]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [55] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR 70: DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [56]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [56] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [57]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -4.38
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.02
         upper limit
    17.26
    Notes
    [57] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [58]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -17.28
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -40.19
         upper limit
    5.63
    Notes
    [58] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [59]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -13.71
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -37.19
         upper limit
    9.77
    Notes
    [59] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [60]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -4.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.67
         upper limit
    18.61
    Notes
    [60] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [61]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -7.6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -29.66
         upper limit
    14.45
    Notes
    [61] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR70: DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [62]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [62] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [63]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.6
         upper limit
    22.68
    Notes
    [63] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [64]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -3.69
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.16
         upper limit
    19.78
    Notes
    [64] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [65]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -6.91
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -30.65
         upper limit
    16.83
    Notes
    [65] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [66]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -14.75
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -35.32
         upper limit
    5.83
    Notes
    [66] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [67]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -7.95
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -28.89
         upper limit
    12.99
    Notes
    [67] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [68]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.6
         upper limit
    22.68
    Notes
    [68] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [69]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -7.95
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -28.89
         upper limit
    12.99
    Notes
    [69] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [70]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -31.65
         upper limit
    8.61
    Notes
    [70] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [71]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -18.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -37.98
         upper limit
    1.34
    Notes
    [71] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [72]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -21.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -42.45
         upper limit
    0.05
    Notes
    [72] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR90: DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [73]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.6
         upper limit
    22.68
    Notes
    [73] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [74]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    1.38
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.15
         upper limit
    18.91
    Notes
    [74] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [75]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -1.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -21.36
         upper limit
    18.37
    Notes
    [75] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [76]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.91
         upper limit
    11.32
    Notes
    [76] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [77]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -15.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -34.29
         upper limit
    4.1
    Notes
    [77] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR30: DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [78]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [78] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [79]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.81
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.04
         upper limit
    21.43
    Notes
    [79] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [80]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -4.38
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.02
         upper limit
    17.26
    Notes
    [80] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [81]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -7.6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -29.66
         upper limit
    14.45
    Notes
    [81] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [82]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -31.65
         upper limit
    8.61
    Notes
    [82] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    ACR100: DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [83]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.81
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.04
         upper limit
    21.43
    Notes
    [83] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Secondary: Percentage of Participants with Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants with Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-label Phase Part 1 [84]
    End point description
    Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of >=30%,50%,70%,90%,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by >=30%. Variables included: number of joints with active arthritis (any joint with swelling, or in absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS (0: no disease activity-100:very severe disease activity); parent/legal guardian/Child evaluation of overall well-being on VAS (0:very well-100 mm:very poor); functional ability (CHAQ Disability Index) ESR. OLPT1 set used. All participants reported as ‘Number of subjects analysed’ contributed data to table; but may not have evaluable data for every row. “n”: participants evaluable for specified time points & used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, and 16
    Notes
    [84] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of participants
    number (confidence interval 95%)
        ACR30: Part 1 Day 7; n=99
    26.26 (17.59 to 34.93)
        ACR30:Part 1 Week 2; n=99
    42.42 (32.69 to 52.16)
        ACR30:Part 1 Week 4; n=97
    68.04 (58.76 to 77.32)
        ACR30:Part 1 Week 8; n=82
    86.59 (79.21 to 93.96)
        ACR30:Part 1 Week 12; n=44
    90.91 (82.41 to 99.40)
        ACR30:Part 1 Week 16; n=24
    83.33 (68.42 to 98.24)
        ACR50:Part 1 Day 7; n=99
    18.18 (10.58 to 25.78)
        ACR50:Part 1 Week 2; n=99
    28.28 (19.41 to 37.15)
        ACR50:Part 1 Week 4; n=97
    44.33 (34.44 to 54.22)
        ACR50:Part 1 Week 8; n=83
    59.04 (48.46 to 69.62)
        ACR50:Part 1 Week 12; n=44
    79.55 (67.63 to 91.46)
        ACR50:Part 1 Week 16; n=24
    75.00 (57.68 to 92.32)
        ACR70:Part 1 Day 7; n=99
    10.10 (4.16 to 16.04)
        ACR70:Part 1 Week 2; n=99
    16.16 (8.91 to 23.41)
        ACR70:Part 1 Week 4; n=97
    19.59 (11.69 to 27.49)
        ACR70:Part 1 Week 8; n=82
    34.15 (23.88 to 44.41)
        ACR70:Part 1 Week 12; n=44
    38.64 (24.25 to 53.02)
        ACR70:Part 1 Week 16; n=24
    33.33 (14.47 to 52.19)
        ACR90:Part 1 Day 7; n=99
    5.05 (0.74 to 9.36)
        ACR90:Part 1 Week 2; n=99
    6.06 (1.36 to 10.76)
        ACR90:Part 1 Week 4; n=97
    11.34 (5.03 to 17.65)
        ACR90:Part 1 Week 8; n=82
    18.29 (9.92 to 26.66)
        ACR90:Part 1 Week 12; n=44
    15.91 (5.10 to 26.72)
        ACR90:Part 1 Week 16; n=24
    16.67 (1.76 to 31.58)
        ACR100:Part 1 Day 7; n=99
    3.03 (0 to 6.41)
        ACR100:Part 1 Week 2; n=99
    5.05 (0.74 to 9.36)
        ACR100:Part 1 Week 4; n=97
    8.25 (2.77 to 13.72)
        ACR100:Part 1 Week 8; n=82
    13.41 (6.04 to 20.79)
        ACR100:Part 1 Week 12; n=44
    9.09 (0.60 to 17.59)
        ACR100:Part 1 Week 16; n=24
    8.33 (0 to 19.39)
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants with Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2 [85]
    End point description
    Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of >=30%,50%,70%,90%,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by >=30%. Variables included: number of joints with active arthritis (i.e. any joint with swelling, or in absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on a VAS from 0=no disease activity to 100=very severe disease activity; parent/ legal guardian/Child evaluation of overall well-being on VAS from 0= very well to 100 mm= very poor; functional ability (CHAQ disability Index) ESR. OLPT2 analysis set was used. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20 and 24
    Notes
    [85] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
    number (confidence interval 95%)
        ACR30:Part 2 Week 4; n=50
    90.00 (81.68 to 98.32)
        ACR30:Part 2 Week 8;n-=40
    87.50 (77.25 to 97.75)
        ACR30:Part 2 Week 12; n=31
    90.32 (79.91 to 100)
        ACR30:Part 2 week 16;n=23
    86.96 (73.19 to 100)
        ACR30:Part 2 Week 20;n=13
    100 (100 to 100)
        ACR30:Part 2 Week 24;n=3
    100 (100 to 100)
        ACR50:Part 2 Week 4;n=50
    86.00 (76.38 to 95.62)
        ACR50:Part 2 Week 8;n=40
    77.50 (64.56 to 90.44)
        ACR50:Part 2 Week 12;n=31
    80.65 (66.74 to 94.55)
        ACR50:Part 2 Week 16;n=23
    73.91 (55.97 to 91.86)
        ACR50:Part 2 Week 20;n=13
    92.31 (77.82 to 100)
        ACR50:Part 2 Week 24;n=3
    100 (100 to 100)
        ACR70:Part 2 Week 4;n=50
    68.00 (55.07 to 80.93)
        ACR70:Part 2 Week 8;n=40
    67.50 (52.98 to 82.02)
        ACR70:Part 2 Week 12;n=31
    70.97 (54.99 to 86.95)
        ACR70:Part 2 Week 16;n=23
    73.91 (55.97 to 91.86)
        ACR70:Part 2 Week 20;-n-13
    92.31 (77.82 to 100)
        ACR70:Part 2 Week 24;n=3
    66.67 (13.32 to 100)
        ACR90:Part 2 Week 4;n=50
    32.00 (19.07 to 44.93)
        ACR90:Part 2 Week 8;n=40
    27.50 (13.66 to 41.34)
        ACR90:Part 2 Week 12;n=31
    22.58 (7.86 to 37.30)
        ACR90:Part 2 Week 16;n=23
    34.78 (15.32 to 54.25)
        ACR90:Part 2 Week 20;n=13
    53.85 (26.75 to 80.95)
        ACR90:Part 2 Week 24;n=3
    33.33 (0 to 86.68)
        ACR100:Part 2 Week 4;n=50
    28.00 (15.55 to 40.45)
        ACR100:Part 2 Week 8;n=40
    27.50 (13.66 to 41.34)
        ACR100:Part 2 Week 12;n=31
    16.13 (3.18 to 29.08)
        ACR100:Part 2 Week 16;n=23
    26.09 (8.14 to 44.03)
        ACR100:Part 2 Week 20;n=13
    38.46 (12.01 to 64.91)
        ACR100:Part 2 Week 24;n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With C-reactive protein (CRP) <= 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants With C-reactive protein (CRP) <= 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [86]
    End point description
    Percentage of participants with CRP <= 10 milligrams per liter (mg/L) along with 95% CI based on normal approximation is reported in this endpoint. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to Day 1 of study treatment), Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16
    Notes
    [86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of participants
    number (confidence interval 95%)
        Baseline; n=100
    30.00 (21.02 to 38.98)
        Part 1 Day 3; n=95
    32.63 (23.20 to 42.06)
        Part 1 Day 7; n=97
    45.36 (35.45 to 55.27)
        Part 1 Week 2; n=97
    49.48 (39.53 to 59.43)
        Part 1 Week 4; n=97
    55.67 (45.78 to 65.56)
        Part 1 Week 8; n=80
    60.00 (49.26 to 70.74)
        Part 1 Week 12; n=44
    59.09 (44.56 to 73.62)
        Part 1 Week 16; n=24
    41.67 (21.94 to 61.39)
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants with Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-label Phase Part 1 [87]
    End point description
    Fever was defined as an oral temperature of ˃38 degree Celsius/100.4 degree Fahrenheit. 95% CI was based on normal approximation. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Subjects Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Days 3, 7 and 14
    Notes
    [87] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 1 Day 3; n=96
    3.13 (0 to 6.61)
        Part 1 Day 7; n=97
    1.03 (0 to 3.04)
        Part 1 Day 14; n=97
    4.12 (0.17 to 8.08)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With C-reactive protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants With C-reactive protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [88]
    End point description
    Percentage of participants with CRP <= 10 mg/L along with 95% CI based on normal approximation is reported in this endpoint. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [88] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 2 Week 4; n=50
    68.00 (55.07 to 80.93)
        Part 2 Week 8; n=40
    62.50 (47.50 to 77.50)
        Part 2 Week 12; n=31
    51.61 (34.02 to 69.21)
        Part 2 Week 16; n=22
    54.55 (33.74 to 75.35)
        Part 2 Week 20; n=13
    76.92 (54.02 to 99.83)
        Part 2 Week 24; n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Absence of Fever due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants With Absence of Fever due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [89]
    End point description
    Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this endpoint. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, 16
    Notes
    [89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 1 Day 7; n=97
    83.51 (76.12 to 90.89)
        Part 1 Week 2; n=97
    82.47 (74.91 to 90.04)
        Part 1 Week 4; n=97
    90.72 (84.95 to 96.50)
        Part 1 Week 8; n=83
    96.39 (92.37 to 100)
        Part 1 Week 12; n=44
    100 (100 to 100)
        Part 1 Week 16; n=24
    95.83 (87.84 to 100)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Absence of Fever due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants With Absence of Fever due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [90]
    End point description
    Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this endpoint. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20 and 24
    Notes
    [90] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 2 Week 4; n=50
    98.00 (94.12 to 100)
        Part 2 Week 8; n=39
    92.31 (83.94 to 100)
        Part 2 Week 12; n=31
    96.77 (90.55 to 100)
        Part 2 Week 16; n=22
    90.91 (78.90 to 100)
        Part 2 Week 20; n=12
    100 (100 to 100)
        Part 2 Week 24; n=3
    100 (100 to 100)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Absence of Fever due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase

    Close Top of page
    End point title
    Percentage of Participants With Absence of Fever due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase [91]
    End point description
    Percentage of participants with absence of fever due sJIA is reported in this endpoint. DBFAS consisted of all randomized participants who received at least one dose of investigational product in the double-blind phase. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [91] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of participants
    number (not applicable)
        DB Week 4
    85.71
    93.55
        DB Week 8
    85.71
    80.65
        DB Week 12
    75.00
    74.19
        DB Week 16
    71.43
    61.29
        DB Week 20
    67.86
    51.61
        DB Week 24
    64.29
    54.84
        DB Week 28
    60.71
    51.61
        DB Week 32
    60.71
    51.61
        DB Week 36
    60.71
    51.61
        DB Week 40
    60.71
    51.61
        DB Week 44
    60.71
    51.61
        DB Week 48
    60.71
    48.39
        DB Week 52
    60.71
    48.39
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [92]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -7.83
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.42
         upper limit
    7.75
    Notes
    [92] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [93]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.81
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -21.43
         upper limit
    23.04
    Notes
    [93] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [94]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    10.14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.82
         upper limit
    34.1
    Notes
    [94] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [95]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    16.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -8.43
         upper limit
    40.92
    Notes
    [95] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [96]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.49
         upper limit
    34.39
    Notes
    [96] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [97]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [97] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [98]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [98] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [99]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [99] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [100]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [100] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [101]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [101] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [102]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    12.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.91
         upper limit
    37.56
    Notes
    [102] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [103]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    5.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.94
         upper limit
    24.08
    Notes
    [103] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [104]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    9.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.13
         upper limit
    34.33
    Notes
    [104] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Secondary: Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 [105]
    End point description
    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n” = participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
    Notes
    [105] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 1 Day 7: n=98
    -5.64 ( 5.20 )
        Part 1 Week 2: n=98
    -8.57 ( 5.97 )
        Part 1 Week 4: n=97
    -11.95 ( 6.53 )
        Part 1 Week 8: n=81
    -15.09 ( 7.27 )
        Part 1 Week 12: n=44
    -15.77 ( 7.24 )
        Part 1 Week 16: n=24
    -14.08 ( 6.09 )
    No statistical analyses for this end point

    Secondary: Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1

    Close Top of page
    End point title
    Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1 [106]
    End point description
    Time to the first adapted JIA ACR 30 response was measured in number of days since Day 1 (day of adapted JIA ACR 30 response – Day 1 + 1) in the Open-Label Phase Part 1. Participants that did not achieve an adapted JIA ACR30 response (absence of fever due to sJIA (temperature ≤38° C/100.4° F) in the preceding 7 days along with an improvement of at least 30% from baseline (Day 1 of study drug before first tofacitinib administration) in at least 3 of the 6 JIA core components, with worsening of > =30 in no more than 1 of the remaining components), which in Part 1 (withdrew from the study) were censored at their last available response assessment in Part 1. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. 95% CI was based on the Brookmeyer and Crowley Method.
    End point type
    Secondary
    End point timeframe
    From Day 1 up to 16 weeks
    Notes
    [106] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Days
        median (confidence interval 95%)
    27.0 (15.0 to 29.0)
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [107]
    End point description
    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24
    Notes
    [107] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -17.05 ( 8.18 )
        Part 2 Week 8; n=40
    -17.13 ( 8.14 )
        Part 2 Week 12; n=31
    -18.17 ( 7.74 )
        Part 2 Week 16; n=23
    -18.89 ( 7.56 )
        Part 2 Week 20; n=13
    -21.14 ( 5.78 )
        Part 2 Week 24; n=3
    -22.17 ( 7.58 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 [108]
    End point description
    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n” = participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
    Notes
    [108] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 1 Day 7; n=97
    -6.25 ( 5.53 )
        Part 1 Week 2; n=96
    -8.55 ( 6.10 )
        Part 1 Week 4; n=97
    -11.88 ( 7.28 )
        Part 1 Week 8; n=80
    -15.07 ( 8.46 )
        Part 1 Week 12; n=44
    -15.19 ( 7.73 )
        Part 1 Week 16; n=24
    -13.10 ( 6.37 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [109]
    End point description
    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n” = participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24
    Notes
    [109] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -17.16 ( 8.87 )
        Part 2 Week 8; n=40
    -17.44 ( 8.03 )
        Part 2 Week 12; n=31
    -18.99 ( 7.67 )
        Part 2 Week 16; n=22
    -20.31 ( 6.41 )
        Part 2 Week 20; n=13
    -22.16 ( 7.05 )
        Part 2 Week 24; n=3
    -25.61 ( 9.82 )
    No statistical analyses for this end point

    Secondary: Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [110]
    End point description
    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [110] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4; (n=27,30)
    1.07 ( 0.84 )
    1.08 ( 0.79 )
        DB Week 8; (n=25,24)
    1.75 ( 1.08 )
    0.81 ( 1.06 )
        DB Week 12; (n=21,22)
    1.47 ( 1.46 )
    1.71 ( 1.40 )
        DB Week 16; (n=21,19)
    0.43 ( 1.03 )
    1.29 ( 1.04 )
        DB Week 20; (n=19,14)
    -1.04 ( 0.65 )
    0.05 ( 0.69 )
        DB Week 24; (n=18,14)
    -0.49 ( 0.57 )
    -0.79 ( 0.60 )
        DB Week 28; (n=17,12)
    2.58 ( 2.05 )
    3.86 ( 2.25 )
        DB Week 32; (n=13,10)
    -0.21 ( 0.77 )
    -0.68 ( 0.83 )
        DB Week 36; (n=13,10)
    -1.52 ( 0.50 )
    -1.26 ( 0.54 )
        DB Week 40; (n=11,9)
    -0.23 ( 0.91 )
    -0.96 ( 0.96 )
        DB Week 44; (n=10,9)
    -1.67 ( 0.75 )
    -0.83 ( 0.79 )
        DB Week 48; (n=8,5)
    -2.29 ( 0.38 )
    -2.06 ( 0.60 )
        DB Week 52; (n=6,4)
    -2.41 ( 0.60 )
    -1.65 ( 1.07 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [111]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.86
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.99
         upper limit
    2.28
    Notes
    [111] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [112]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.54
         upper limit
    4.06
    Notes
    [112] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [113]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.94
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.25
         upper limit
    4.12
    Notes
    [113] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [114]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.4
         upper limit
    2.38
    Notes
    [114] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [115]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.86
         upper limit
    1.35
    Notes
    [115] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [116]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.18
         upper limit
    3.63
    Notes
    [116] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [117]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.83
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.22
         upper limit
    1.56
    Notes
    [117] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [118]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.76
         upper limit
    1.3
    Notes
    [118] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [119]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.48
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.98
         upper limit
    2.93
    Notes
    [119] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [120]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.75
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.43
         upper limit
    1.93
    Notes
    [120] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [121]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.46
         upper limit
    2.06
    Notes
    [121] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [122]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.12
         upper limit
    0.94
    Notes
    [122] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [123]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.28
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -7.85
         upper limit
    5.29
    Notes
    [123] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [124]
    End point description
    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 [very well] to 10 [very poor]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [124] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4; (n=26,31)
    1.62 ( 0.96 )
    0.71 ( 0.90 )
        DB Week 8; (n=25,25)
    2.12 ( 0.95 )
    0.01 ( 0.93 )
        DB Week 12; (n=21,22)
    1.78 ( 1.46 )
    1.80 ( 1.40 )
        DB Week 16; (n=21,19)
    0.84 ( 1.09 )
    1.95 ( 1.08 )
        DB Week 20; (n=19,15)
    -0.17 ( 0.84 )
    0.36 ( 0.87 )
        DB Week 24; (n=18,15)
    1.58 ( 1.04 )
    -0.26 ( 1.08 )
        DB Week 28; (n=17,12)
    2.64 ( 1.86 )
    2.72 ( 2.04 )
        DB Week 32; (n=12,9)
    0.49 ( 0.99 )
    1.18 ( 1.07 )
        DB Week 36; (n=13,10)
    -1.59 ( 0.50 )
    -1.24 ( 0.53 )
        DB Week 40; (n=11,9)
    0.38 ( 1.15 )
    0.41 ( 1.21 )
        DB Week 44; (n=10,9)
    -1.09 ( 0.99 )
    1.50 ( 1.02 )
        DB Week 48; (n=8,5)
    -2.04 ( 0.51 )
    -1.23 ( 0.76 )
        DB Week 52; (n=6,4)
    -2.31 ( 0.60 )
    -1.85 ( 1.10 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [125]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.9
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.8
         upper limit
    3.61
    Notes
    [125] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [126]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    2.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.64
         upper limit
    4.86
    Notes
    [126] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [127]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.25
         upper limit
    4.21
    Notes
    [127] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [128]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.32
         upper limit
    2.09
    Notes
    [128] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [129]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.53
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.04
         upper limit
    1.98
    Notes
    [129] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [130]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.29
         upper limit
    4.97
    Notes
    [130] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [131]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.08
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.89
         upper limit
    5.72
    Notes
    [131] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [132]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.63
         upper limit
    3.58
    Notes
    [132] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [133]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.35
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.89
         upper limit
    1.19
    Notes
    [133] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [134]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.69
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.79
         upper limit
    2.41
    Notes
    [134] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [135]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -2.59
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.67
         upper limit
    0.49
    Notes
    [135] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [136]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.82
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.82
         upper limit
    1.19
    Notes
    [136] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [137]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.27
         upper limit
    2.36
    Notes
    [137] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [138]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [138] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Joints
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -7.78 ( 7.78 )
        Part 2 Week 8; n=40
    -7.73 ( 8.40 )
        Part 2 Week 12; n=31
    -9.26 ( 7.98 )
        Part 2 Week 16; n=23
    -10.00 ( 7.99 )
        Part 2 Week 20; n=13
    -10.85 ( 7.83 )
        Part 2 Week 24; n=3
    -13.67 ( 11.02 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in Number of Joints with Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [139]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
    Notes
    [139] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Joints
    arithmetic mean (standard deviation)
        Part 1 Day 7; n=99
    -2.96 ( 4.17 )
        Part 1 Week 2; n=99
    -4.21 ( 5.31 )
        Part 1 Week 4; n=97
    -6.03 ( 6.04 )
        Part 1 Week 8; n=83
    -7.80 ( 9.25 )
        Part 1 Week 12; n=44
    -7.52 ( 7.38 )
        Part 1 Week 16; n=24
    -6.38 ( 7.87 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [140]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
    Notes
    [140] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Joints
    arithmetic mean (standard deviation)
        Part 1 Day 7; n=99
    -1.83 ( 4.26 )
        Part 1 Week 2; n=99
    -2.06 ( 4.70 )
        Part 1 Week 4; n=97
    -2.90 ( 5.42 )
        Part 1 Week 8; n=83
    -4.36 ( 8.59 )
        Part 1 Week 12; n=44
    -3.64 ( 6.05 )
        Part 1 Week 16; n=24
    -2.33 ( 3.48 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [141]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [141] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Joints
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -4.26 ( 6.75 )
        Part 2 Week 8; n=40
    -3.90 ( 6.08 )
        Part 2 Week 12; n=31
    -5.81 ( 7.48 )
        Part 2 Week 16; n=23
    -5.74 ( 7.13 )
        Part 2 Week 20; n=13
    -5.92 ( 9.32 )
        Part 2 Week 24; n=3
    -15.67 ( 11.02 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [142]
    End point description
    Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
    Notes
    [142] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 1 Day 7; n=99
    -1.18 ( 1.36 )
        Part 1 Week 2; n=99
    -1.82 ( 1.68 )
        Part 1 Week 4; n=97
    -2.62 ( 1.75 )
        Part 1 Week 8; n=83
    -3.40 ( 2.01 )
        Part 1 Week 12; n=44
    -3.66 ( 2.08 )
        Part 1 Week 16; n=24
    -3.50 ( 1.93 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [143]
    End point description
    Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [143] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -4.54 ( 2.10 )
        Part 2 Week 8; n=40
    -4.53 ( 1.74 )
        Part 2 Week 12; n=31
    -4.65 ( 1.57 )
        Part 2 Week 16; n=23
    -4.89 ( 1.77 )
        Part 2 Week 20; n=13
    -5.62 ( 1.21 )
        Part 2 Week 24; n=3
    -6.17 ( 1.44 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [144]
    End point description
    ESR was determined using an ESR testing kit. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [144] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Millimeter per hour
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -33.64 ( 28.16 )
        Part 2 Week 8; n=40
    -30.73 ( 27.11 )
        Part 2 Week 12; n=31
    -27.52 ( 28.13 )
        Part 2 Week 16; n=23
    -23.48 ( 24.70 )
        Part 2 Week 20; n=13
    -37.54 ( 20.93 )
        Part 2 Week 24; n=3
    -24.33 ( 6.03 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [145]
    End point description
    ESR was determined using an ESR testing kit. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
    Notes
    [145] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Millimeter per hour
    arithmetic mean (standard deviation)
        Part 1 Day 7; n=98
    -11.00 ( 16.96 )
        Part 1 Week 2; n=99
    -18.60 ( 19.78 )
        Part 1 Week 4; n=97
    -24.70 ( 23.86 )
        Part 1 Week 8; n=81
    -30.59 ( 23.12 )
        Part 1 Week 12; n=44
    -31.74 ( 21.75 )
        Part 1 Week 16; n=24
    -27.65 ( 28.84 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Child Health Assessment Questionnaire (CHAQ)- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in Child Health Assessment Questionnaire (CHAQ)- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [146]
    End point description
    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle visual analog scale (VAS) where ‘0= Very Well and 10=Very Poorly. OLPT1 analysis set included all participants who were enrolled into the open-label part 1 phase of the study and received at least one dose of investigational product in part 1. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Days 3,7, Part 1 Weeks 2, 4, 8, 12, 16
    Notes
    [146] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 1 Day 3; n=96
    -0.73 ( 1.53 )
        Part 1 Day 7; n=99
    -1.36 ( 1.91 )
        Part 1 Week 2; n=98
    -1.96 ( 1.89 )
        Part 1 Week 4; n=97
    -2.65 ( 2.44 )
        Part 1 Week 8; n=83
    -3.35 ( 2.38 )
        Part 1 Week 12; n=44
    -3.45 ( 2.45 )
        Part 1 Week 16; n=24
    -3.48 ( 2.78 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [147]
    End point description
    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where ‘0= Very Well and 10=Very Poorly. OLPT2 analysis set included all participants who were enrolled into the open-label part 2 phase of the study and received at least one dose of investigational product in part 2. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [147] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -4.09 ( 2.68 )
        Part 2 Week 8; n=40
    -4.50 ( 2.88 )
        Part 2 Week 12; n=31
    -4.73 ( 2.83 )
        Part 2 Week 16; n=23
    -5.11 ( 2.50 )
        Part 2 Week 20; n=13
    -5.65 ( 2.89 )
        Part 2 Week 24; n=3
    -6.33 ( 2.31 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [148]
    End point description
    CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall Well-being. CHAQ disability index consisted of 30 items in 8 areas: 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to 3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid. OLP1 set was used. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here, “n”:number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
    Notes
    [148] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 1 Day 7; n=99
    -0.21 ( 0.35 )
        Part 1 Week 2; n=99
    -0.38 ( 0.43 )
        Part 1 Week 4; n=97
    -0.52 ( 0.56 )
        Part 1 Week 8; n=83
    -0.59 ( 0.57 )
        Part 1 Week 12; n=44
    -0.51 ( 0.56 )
        Part 1 Week 16; n=24
    -0.74 ( 0.73 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in CHAQ - Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in CHAQ - Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [149]
    End point description
    CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. CHAQ disability index consisted of 30 items in 8 areas, 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to-3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid. OLPT2 set was used. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here, “n”:number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [149] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 2 Week 4; n=50
    -0.79 ( 0.63 )
        Part 2 Week 8; n=40
    -0.78 ( 0.76 )
        Part 2 Week 12; n=31
    -0.85 ( 0.80 )
        Part 2 Week 16; n=23
    -0.67 ( 0.74 )
        Part 2 Week 20; n=13
    -0.93 ( 0.77 )
        Part 2 Week 24; n=3
    -0.96 ( 0.92 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Open-Label Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [150]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [150] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Joints
    least squares mean (standard error)
        DB Week 4 (n=27,31)
    -6.53 ( 0.34 )
    -7.39 ( 0.32 )
        DB Week 8(n=25,25)
    -6.36 ( 0.38 )
    -7.69 ( 0.38 )
        DB Week 12 (n=21,23)
    -5.92 ( 0.80 )
    -7.36 ( 0.76 )
        DB Week 16 (n=21,20)
    -7.34 ( 0.25 )
    -7.37 ( 0.25 )
        DB Week 20 (n=19,15)
    -7.41 ( 0.18 )
    -7.51 ( 0.20 )
        DB Week 24 (n=18,15)
    -7.33 ( 0.13 )
    -7.76 ( 0.13 )
        DB Week 28 (n=17,12)
    -6.36 ( 0.59 )
    -6.56 ( 0.67 )
        DB Week 32 (n=13,10)
    -7.27 ( 0.17 )
    -7.76 ( 0.19 )
        DB Week 36 (n=13,10)
    -7.43 ( 0.14 )
    -7.78 ( 0.16 )
        DB Week 40(n=11,9)
    -7.06 ( 0.24 )
    -7.58 ( 0.27 )
        DB Week 44 (n=10, 9)
    -7.39 ( 0.33 )
    -7.20 ( 0.35 )
        DB Week 48 (n=8, 5)
    -7.54 ( 0.20 )
    -7.75 ( 0.25 )
        DB Week 52 (n=6, 5)
    -7.46 ( 0.26 )
    -7.51 ( 0.28 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [151]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.43
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.79
         upper limit
    3.66
    Notes
    [151] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [152]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.25
         upper limit
    2.4
    Notes
    [152] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [153]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.86
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.08
         upper limit
    1.79
    Notes
    [153] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [154]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.8
         upper limit
    0.92
    Notes
    [154] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [155]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.04
         upper limit
    1.03
    Notes
    [155] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [156]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.35
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.09
         upper limit
    0.79
    Notes
    [156] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [157]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.23
         upper limit
    1.28
    Notes
    [157] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [158]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.2
         upper limit
    0.83
    Notes
    [158] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [159]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.49
         upper limit
    0.91
    Notes
    [159] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [160]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.06
         upper limit
    0.81
    Notes
    [160] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [161]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.43
         upper limit
    0.64
    Notes
    [161] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [162]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.7
         upper limit
    0.74
    Notes
    [162] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [163]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.64
         upper limit
    2.06
    Notes
    [163] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.

    Secondary: Change From Double-Blind Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in Number of Joints with Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [164]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Participants were reported under the treatment they were randomised. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [164] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Joints
    least squares mean (standard error)
        DB Week 4 (n=27,31)
    0.38 ( 0.26 )
    0.09 ( 0.24 )
        DB Week 8 (n=25,25)
    0.78 ( 0.38 )
    -0.23 ( 0.37 )
        DB Week 12 (n=21,23)
    1.47 ( 0.85 )
    0.22 ( 0.81 )
        DB Week 16(n=21,20)
    0.05 ( 0.27 )
    -0.05 ( 0.27 )
        DB Week 20(n=19,15)
    -0.15 ( 0.15 )
    -0.02 ( 0.17 )
        DB Week 24 (n=18,15)
    -0.06 ( 0.12 )
    -0.39 ( 0.13 )
        DB Week 28 (n=17,12)
    0.71 ( 0.70 )
    0.88 ( 0.84 )
        DB Week 32 (n=13,10)
    0.01 ( 0.18 )
    -0.41 ( 0.20 )
        DB Week 36 (n=13,10)
    -0.14 ( 0.15 )
    -0.47 ( 0.17 )
        DB Week 40 (n=11,9)
    0.31 ( 0.25 )
    -0.37 ( 0.28 )
        DB Week 44(n=10, 9)
    -0.05 ( 0.35 )
    0.11 ( 0.38 )
        DB Week 48(n=8, 5)
    -0.20 ( 0.21 )
    -0.56 ( 0.27 )
        DB Week 52(n=6, 5)
    -0.14 ( 0.28 )
    -0.38 ( 0.34 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [165]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.13
         upper limit
    3.64
    Notes
    [165] - DB Week 12
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [166]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.06
         upper limit
    2.08
    Notes
    [166] - DB Week 8
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [167]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.43
         upper limit
    1
    Notes
    [167] - DB Week 4
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [168]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.03
         upper limit
    0.68
    Notes
    [168] - DB Week 24
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [169]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.13
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.58
         upper limit
    0.33
    Notes
    [169] - DB Week 20
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [170]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.68
         upper limit
    0.88
    Notes
    [170] - DB Week 16
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [171]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.17
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.42
         upper limit
    2.08
    Notes
    [171] - DB Week 28
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [172]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.42
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.14
         upper limit
    0.97
    Notes
    [172] - DB Week 32
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [173]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.15
         upper limit
    0.79
    Notes
    [173] - DB Week 36
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [174]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.68
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.14
         upper limit
    1.49
    Notes
    [174] - DB Week 40
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [175]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.28
         upper limit
    0.96
    Notes
    [175] - DB Week 44
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [176]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.37
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.43
         upper limit
    1.16
    Notes
    [176] - DB Week 48
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [177]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.82
         upper limit
    1.3
    Notes
    [177] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Open-Label Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [178]
    End point description
    The parent was asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid. DBFAS set. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here “n”=number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [178] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    arithmetic mean (standard deviation)
        DB Week 4 (n=27,31)
    -0.81 ( 0.10 )
    -1.03 ( 0.09 )
        DB Week 8(n=25,25)
    -0.93 ( 0.08 )
    -1.02 ( 0.08 )
        DB Week 12 (n=21,23)
    -0.99 ( 0.08 )
    -1.04 ( 0.07 )
        DB Week 16(n=21,20)
    -0.95 ( 0.09 )
    -1.05 ( 0.09 )
        DB Week 20 (n=19,15)
    -1.02 ( 0.07 )
    -1.21 ( 0.07 )
        DB Week 24(n=18,15)
    -0.94 ( 0.08 )
    -1.05 ( 0.08 )
        DB Week 28(n=17,12)
    -0.94 ( 0.08 )
    -1.01 ( 0.09 )
        DB Week 32 (n=13,10)
    -0.96 ( 0.07 )
    -1.11 ( 0.07 )
        DB Week 36 (n=13,10)
    -1.05 ( 0.08 )
    -1.16 ( 0.09 )
        DB Week 40 (n=11,9)
    -1.07 ( 0.07 )
    -1.22 ( 0.08 )
        DB Week 44 (n=10, 9)
    -1.04 ( 0.09 )
    -1.08 ( 0.09 )
        DB Week 48(n=8, 5)
    -1.01 ( 0.09 )
    -1.10 ( 0.11 )
        DB Week 52 (n=6, 5)
    -1.04 ( 0.10 )
    -1.13 ( 0.12 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [179]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.15
         upper limit
    0.32
    Notes
    [179] - DB Week 8
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [180]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.07
         upper limit
    0.5
    Notes
    [180] - DB Week 4
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [181]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.17
         upper limit
    0.28
    Notes
    [181] - DB Week 12
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [182]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.16
         upper limit
    0.36
    Notes
    [182] - DB Week 16
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [183]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.12
         upper limit
    0.35
    Notes
    [183] - DB Week 24
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [184]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.01
         upper limit
    0.38
    Notes
    [184] - DB Week 20
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [185]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    0.31
    Notes
    [185] - DB Week 28
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [186]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.06
         upper limit
    0.38
    Notes
    [186] - DB Week 40
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [187]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.14
         upper limit
    0.36
    Notes
    [187] - DB Week 36
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [188]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.06
         upper limit
    0.37
    Notes
    [188] - DB Week 32
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [189]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.04
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.22
         upper limit
    0.3
    Notes
    [189] - DB Week 44
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [190]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.2
         upper limit
    0.38
    Notes
    [190] - DB Week 48
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, open-label baseline value, and open-label baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [191]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.24
         upper limit
    0.42
    Notes
    [191] - DB Week 52

    Secondary: Change From Double Blind Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double Blind Baseline in Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [192]
    End point description
    The parent was asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid. DBFAS set. All participants reported under “Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here, “n” =number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [192] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4(n=27,31)
    0.04 ( 0.06 )
    -0.02 ( 0.06 )
        DB Week 8 (n=25,25)
    -0.03 ( 0.06 )
    -0.01 ( 0.06 )
        DB Week 12(n=21,23)
    -0.06 ( 0.06 )
    -0.05 ( 0.06 )
        DB Week 16(n=21,20)
    -0.03 ( 0.07 )
    -0.05 ( 0.07 )
        DB Week 20(n=19,15)
    -0.08 ( 0.06 )
    -0.23 ( 0.06 )
        DB Week 24 (n=18,15)
    0.06 ( 0.08 )
    -0.09 ( 0.08 )
        DB Week 28(n=17,12)
    0.05 ( 0.08 )
    -0.04 ( 0.09 )
        DB Week 32(n=13,10)
    0.02 ( 0.07 )
    -0.13 ( 0.07 )
        DB Week 36(n=13,10)
    -0.03 ( 0.09 )
    -0.19 ( 0.09 )
        DB Week 40 (n=11,9)
    -0.09 ( 0.07 )
    -0.25 ( 0.07 )
        DB Week 44 (n=10, 9)
    -0.06 ( 0.09 )
    -0.10 ( 0.09 )
        DB Week 48(n=8, 5)
    -0.03 ( 0.09 )
    -0.19 ( 0.12 )
        DB Week 52 (n=6, 5)
    -0.05 ( 0.10 )
    -0.21 ( 0.13 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [193]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.1
         upper limit
    0.24
    Notes
    [193] - DB Week 4
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [194]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.19
         upper limit
    0.15
    Notes
    [194] - DB Week 8
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [195]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.19
         upper limit
    0.16
    Notes
    [195] - DB Week 12
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [196]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.2
         upper limit
    0.23
    Notes
    [196] - DB Week 16
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [197]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.02
         upper limit
    0.32
    Notes
    [197] - DB Week 20
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [198]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.09
         upper limit
    0.4
    Notes
    [198] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [199]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.16
         upper limit
    0.34
    Notes
    [199] - DB Week 28
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [200]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.17
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.06
         upper limit
    0.39
    Notes
    [200] - DB Week 40
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [201]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.1
         upper limit
    0.43
    Notes
    [201] - DB Week 36
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [202]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.05
         upper limit
    0.36
    Notes
    [202] - DB Week 32
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [203]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.04
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.22
         upper limit
    0.3
    Notes
    [203] - DB Week 44
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [204]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    0.49
    Notes
    [204] - DB Week 48
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [205]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.23
         upper limit
    0.55
    Notes
    [205] - DB Week 52

    Secondary: Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Open-Label Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [206]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [206] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Joints
    least squares mean (standard error)
        DB Week 4 (n=27,31)
    -2.47 ( 0.43 )
    -2.69 ( 0.41 )
        DB Week 8 (n=25,25)
    -2.31 ( 0.45 )
    -2.89 ( 0.44 )
        DB Week 12(n=21,23)
    -2.09 ( 0.71 )
    -3.29 ( 0.68 )
        DB Week 16(n=21,20)
    -2.76 ( 0.44 )
    -2.70 ( 0.43 )
        DB Week 20(n=19,15)
    -2.79 ( 0.19 )
    -3.05 ( 0.19 )
        DB Week 24(n=18,15)
    -2.98 ( 0.19 )
    -3.07 ( 0.19 )
        DB Week 28(n=17,12)
    -2.56 ( 0.54 )
    -2.10 ( 0.56 )
        DB Week 32(n=13,10)
    -2.89 ( 0.18 )
    -3.24 ( 0.19 )
        DB Week 36(n=13,10)
    -2.90 ( 0.19 )
    -3.21 ( 0.21 )
        DB Week 40(n=11,9)
    -2.96 ( 0.24 )
    -3.24 ( 0.25 )
        DB Week 44(n=10,9)
    -2.95 ( 0.25 )
    -3.24 ( 0.26 )
        DB Week 48(n=8,5)
    -3.03 ( 0.27 )
    -3.25 ( 0.30 )
        DB Week 52(n=6,5)
    -2.75 ( 0.36 )
    -3.20 ( 0.36 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [207]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.58
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.68
         upper limit
    1.84
    Notes
    [207] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [208]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.97
         upper limit
    1.4
    Notes
    [208] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [209]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.29
         upper limit
    0.82
    Notes
    [209] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [210]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.46
         upper limit
    0.64
    Notes
    [210] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [211]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.66
         upper limit
    1.57
    Notes
    [211] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [212]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.35
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    0.88
    Notes
    [212] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [213]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.26
         upper limit
    0.88
    Notes
    [213] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [214]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.28
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.43
         upper limit
    0.99
    Notes
    [214] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [215]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.45
         upper limit
    1.03
    Notes
    [215] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [216]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.22
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.63
         upper limit
    1.08
    Notes
    [216] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [217]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.3
         upper limit
    1.18
    Notes
    [217] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [218]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.77
         upper limit
    3.16
    Notes
    [218] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [219]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.05
         upper limit
    1.13
    Notes
    [219] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.

    Secondary: Change From Double-Blind Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in Number of Joints with Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [220]
    End point description
    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [220] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Joints
    least squares mean (standard error)
        DB Week 4 (n=27,31)
    0.08 ( 0.22 )
    0.21 ( 0.20 )
        DB Week 8 (n=25,25)
    0.45 ( 0.42 )
    0.06 ( 0.42 )
        DB Week 12 (n=21,23)
    0.48 ( 0.44 )
    -0.23 ( 0.42 )
        DB Week 16 (n=21,20)
    -0.30 ( 0.17 )
    0.10 ( 0.17 )
        DB Week 20 (n=19,15)
    -0.36 ( 0.10 )
    -0.19 ( 0.11 )
        DB Week 24(n=18,15)
    -0.53 ( 0.10 )
    -0.22 ( 0.11 )
        DB Week 28 (n=17,12)
    -0.05 ( 0.40 )
    1.05 ( 0.46 )
        DB Week 32 (n=13,10)
    -0.41 ( 0.10 )
    -0.48 ( 0.12 )
        DB Week 36 (n=13,10)
    -0.48 ( 0.09 )
    -0.46 ( 0.10 )
        DB Week 40 (n=11,9)
    -0.48 ( 0.15 )
    -0.43 ( 0.17 )
        DB Week 44 (n=10, 9)
    -0.47 ( 0.16 )
    -0.43 ( 0.17 )
        DB Week 48(n=8, 5)
    -0.50 ( 0.20 )
    -0.47 ( 0.24 )
        DB Week 52 (n=6, 5)
    -0.21 ( 0.31 )
    -0.42 ( 0.33 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [221]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.13
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.73
         upper limit
    0.47
    Notes
    [221] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [222]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.39
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.81
         upper limit
    1.59
    Notes
    [222] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [223]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.54
         upper limit
    1.95
    Notes
    [223] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [224]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.9
         upper limit
    0.1
    Notes
    [224] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [225]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.46
         upper limit
    0.13
    Notes
    [225] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [226]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.63
         upper limit
    -0.01
    Notes
    [226] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [227]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.34
         upper limit
    0.15
    Notes
    [227] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [228]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.26
         upper limit
    0.4
    Notes
    [228] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [229]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.3
         upper limit
    0.26
    Notes
    [229] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [230]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.53
         upper limit
    0.43
    Notes
    [230] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [231]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.56
         upper limit
    0.46
    Notes
    [231] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [232]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.74
         upper limit
    0.69
    Notes
    [232] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [233]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.91
         upper limit
    1.32
    Notes
    [233] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [234]
    End point description
    Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Participants were reported under the treatment they were randomised. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [234] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4(n=27,31)
    -4.22 ( 0.33 )
    -5.22 ( 0.32 )
        DB Week 8 (n=25,25)
    -4.23 ( 0.32 )
    -5.55 ( 0.32 )
        DB Week 12(n=21,23)
    -4.89 ( 0.36 )
    -5.42 ( 0.34 )
        DB Week 16 (n=21,20)
    -4.96 ( 0.32 )
    -5.22 ( 0.32 )
        DB Week 20(n=19,15)
    -5.32 ( 0.23 )
    -5.64 ( 0.24 )
        DB Week 24 (n=18,15)
    -5.11 ( 0.22 )
    -5.66 ( 0.23 )
        DB Week 28 (n=17,12)
    -5.06 ( 0.37 )
    -5.26 ( 0.40 )
        DB Week 32 (n=13,10)
    -5.08 ( 0.26 )
    -5.71 ( 0.28 )
        DB Week 36 (n=13,10)
    -5.55 ( 0.16 )
    -6.03 ( 0.18 )
        DB Week 40 (n=11,9)
    -5.23 ( 0.30 )
    -5.88 ( 0.33 )
        DB Week 44(n=10, 9)
    -5.65 ( 0.21 )
    -5.87 ( 0.22 )
        DB Week 48(n=8, 5)
    -5.87 ( 0.18 )
    -6.14 ( 0.24 )
        DB Week 52 (n=6, 5)
    -5.86 ( 0.26 )
    -5.97 ( 0.33 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [235]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.09
         upper limit
    1.92
    Notes
    [235] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [236]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.4
         upper limit
    2.22
    Notes
    [236] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [237]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.53
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.47
         upper limit
    1.53
    Notes
    [237] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [238]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.63
         upper limit
    1.16
    Notes
    [238] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [239]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.33
         upper limit
    0.97
    Notes
    [239] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [240]
    Method
    Mixed Model for Repeated Measures
    Parameter type
    Difference in LS Mean
    Point estimate
    0.55
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.1
         upper limit
    1.2
    Notes
    [240] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [241]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.93
         upper limit
    1.33
    Notes
    [241] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [242]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.4
         upper limit
    0.85
    Notes
    [242] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [243]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.62
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.17
         upper limit
    1.42
    Notes
    [243] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [244]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.48
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.02
         upper limit
    0.98
    Notes
    [244] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [245]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.3
         upper limit
    1.58
    Notes
    [245] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [246]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.36
         upper limit
    0.88
    Notes
    [246] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [247]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.87
         upper limit
    1.09
    Notes
    [247] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-label baseline value, and Open-label baseline value by visit interaction.

    Secondary: Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [248]
    End point description
    Physician global evaluation of disease activity was assessed on a VAS ranging from 0 to 10 mm, where 0=no activity and 10=maximum activity. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Participants were reported under the treatment they were randomised. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [248] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4 (n=27,31)
    0.16 ( 0.25 )
    0.21 ( 0.24 )
        DB Week 8(n=25,25)
    0.45 ( 0.32 )
    -0.14 ( 0.32 )
        DB Week 12 (n=21,23)
    0.10 ( 0.40 )
    -0.02 ( 0.39 )
        DB Week 16(n=21,20)
    -0.11 ( 0.34 )
    0.15 ( 0.34 )
        DB Week 20 (n=19,15)
    -0.51 ( 0.22 )
    -0.35 ( 0.23 )
        DB Week 24 (n=18,15)
    -0.32 ( 0.22 )
    -0.37 ( 0.22 )
        DB Week 28 (n=17,12)
    0.09 ( 0.43 )
    0.19 ( 0.47 )
        DB Week 32 (n=13,10)
    -0.11 ( 0.29 )
    -0.42 ( 0.32 )
        DB Week 36(n=13,10)
    -0.74 ( 0.17 )
    -0.92 ( 0.18 )
        DB Week 40 (n=11,9)
    -0.17 ( 0.35 )
    -0.53 ( 0.37 )
        DB Week 44 (n=10, 9)
    -0.79 ( 0.21 )
    -0.70 ( 0.22 )
        DB Week 48(n=8, 5)
    -1.03 ( 0.20 )
    -1.09 ( 0.29 )
        DB Week 52 (n=6, 5)
    -1.00 ( 0.27 )
    -0.92 ( 0.39 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [249]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.58
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.37
         upper limit
    1.53
    Notes
    [249] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [250]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.77
         upper limit
    0.67
    Notes
    [250] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [251]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.83
         upper limit
    0.52
    Notes
    [251] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [252]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.61
         upper limit
    0.71
    Notes
    [252] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [253]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.08
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.1
         upper limit
    0.94
    Notes
    [253] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [254]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.61
         upper limit
    1.23
    Notes
    [254] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [255]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.18
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.34
         upper limit
    0.71
    Notes
    [255] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [256]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.36
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.74
         upper limit
    1.46
    Notes
    [256] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [257]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.75
         upper limit
    0.56
    Notes
    [257] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [258]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.68
         upper limit
    0.81
    Notes
    [258] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [259]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.27
         upper limit
    0.74
    Notes
    [259] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [260]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.06
         upper limit
    1.3
    Notes
    [260] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [261]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.45
         upper limit
    1.25
    Notes
    [261] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [262]
    End point description
    DBFAS was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [262] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Millimeter per hour (mm/h)
    least squares mean (standard error)
        DB Week 4 (n=27,31)
    -32.65 ( 4.72 )
    -31.19 ( 4.49 )
        DB Week 8(n=25,25)
    -36.55 ( 4.38 )
    -29.32 ( 4.29 )
        DB Week 12(n=21,23)
    -38.30 ( 4.50 )
    -31.69 ( 4.35 )
        DB Week 16(n=21,20)
    -39.52 ( 4.06 )
    -31.02 ( 4.06 )
        DB Week 20 (n=19,15)
    -41.82 ( 2.22 )
    -37.86 ( 2.32 )
        DB Week 24(n=18,15)
    -42.25 ( 2.25 )
    -40.81 ( 2.33 )
        DB Week 28 (n=17,12)
    -37.83 ( 4.07 )
    -33.51 ( 4.39 )
        DB Week 32 (n=13,10)
    -37.90 ( 3.67 )
    -35.04 ( 3.91 )
        DB Week 36 (n=13,10)
    -39.36 ( 4.49 )
    -28.41 ( 4.79 )
        DB Week 40(n=11,9)
    -39.98 ( 4.12 )
    -35.70 ( 4.31 )
        DB Week 44 (n=10, 9)
    -47.16 ( 2.28 )
    -38.84 ( 2.34 )
        DB Week 48 (n=8, 5)
    -47.16 ( 2.29 )
    -42.32 ( 2.72 )
        DB Week 52 (n=6, 4)
    -51.46 ( 1.08 )
    -50.12 ( 1.24 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [263]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -7.22
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -19.62
         upper limit
    5.17
    Notes
    [263] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [264]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -14.59
         upper limit
    11.66
    Notes
    [264] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [265]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -8.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.28
         upper limit
    3.27
    Notes
    [265] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [266]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -4.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.67
         upper limit
    8.03
    Notes
    [266] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [267]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -8.09
         upper limit
    5.21
    Notes
    [267] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [268]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -3.95
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -10.53
         upper limit
    2.62
    Notes
    [268] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [269]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -6.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -19.36
         upper limit
    6.14
    Notes
    [269] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [270]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.34
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.16
         upper limit
    2.48
    Notes
    [270] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [271]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -4.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.6
         upper limit
    2.92
    Notes
    [271] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [272]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -8.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.2
         upper limit
    -1.43
    Notes
    [272] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [273]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -10.95
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.63
         upper limit
    2.73
    Notes
    [273] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [274]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -2.86
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.97
         upper limit
    8.25
    Notes
    [274] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [275]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -4.28
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.74
         upper limit
    8.18
    Notes
    [275] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open label baseline value, and Open-label baseline value by visit interaction.

    Secondary: Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [276]
    End point description
    DBFAS set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [276] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Millimeter/ hour (mm/h)
    least squares mean (standard error)
        DB Week 4 (n=27,30)
    3.35 ( 3.71 )
    9.41 ( 3.50 )
        DB Week 8 (n=25,24)
    1.94 ( 3.97 )
    12.39 ( 3.93 )
        DB Week 12 (n=21,22)
    1.42 ( 4.53 )
    12.28 ( 4.40 )
        DB Week 16(n=21,19)
    0.45 ( 4.32 )
    13.59 ( 4.35 )
        DB Week 20(n=19,14)
    -2.04 ( 2.17 )
    4.98 ( 2.31 )
        DB Week 24(n=18,14)
    -2.51 ( 2.14 )
    2.01 ( 2.28 )
        DB Week 28(n=17,12)
    1.73 ( 4.19 )
    11.08 ( 4.55 )
        DB Week 32(n=13,10)
    2.01 ( 3.78 )
    8.77 ( 4.05 )
        DB Week 36(n=13,10)
    0.88 ( 4.83 )
    16.37 ( 5.17 )
        DB Week 40(n=11,9)
    0.34 ( 4.25 )
    8.33 ( 4.47 )
        DB Week 44(n=10,9)
    -7.05 ( 2.34 )
    3.44 ( 2.41 )
        DB Week 48(n=8,5)
    -8.07 ( 2.38 )
    -2.14 ( 2.96 )
        DB Week 52(n=6,4)
    -11.70 ( 1.39 )
    -9.14 ( 1.73 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [277]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -7.99
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -21
         upper limit
    5.03
    Notes
    [277] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [278]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -6.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.3
         upper limit
    4.19
    Notes
    [278] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [279]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -10.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -21.68
         upper limit
    0.77
    Notes
    [279] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [280]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -10.86
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.75
         upper limit
    2.03
    Notes
    [280] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [281]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -13.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.83
         upper limit
    -0.46
    Notes
    [281] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [282]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -7.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.56
         upper limit
    -0.47
    Notes
    [282] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [283]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -4.53
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -11
         upper limit
    1.95
    Notes
    [283] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [284]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -9.35
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -22.24
         upper limit
    3.54
    Notes
    [284] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [285]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -6.75
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -18.34
         upper limit
    4.83
    Notes
    [285] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [286]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -15.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -30.36
         upper limit
    -0.63
    Notes
    [286] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [287]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -10.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -17.67
         upper limit
    -3.31
    Notes
    [287] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [288]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -5.93
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.53
         upper limit
    1.67
    Notes
    [288] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [289]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -2.57
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -6.37
         upper limit
    1.24
    Notes
    [289] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [290]
    End point description
    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where ‘0’= Very Well’ and ‘10=Very Poorly. DBFAS set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [290] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4 (n-27,30)
    -4.31 ( 0.37 )
    -5.52 ( 0.34 )
        DB Week 8 (n=25,25)
    -4.56 ( 0.36 )
    -5.38 ( 0.35 )
        DB Week 12(n=21,23)
    -4.97 ( 0.34 )
    -5.28 ( 0.33 )
        DB Week 16(n=21,20)
    -4.88 ( 0.29 )
    -5.46 ( 0.29 )
        DB Week 20 (n=19,15)
    -5.19 ( 0.32 )
    -5.36 ( 0.34 )
        DB Week 24 (n=18,15)
    -4.97 ( 0.29 )
    -5.62 ( 0.30 )
        DB Week 28(n=17,12)
    -5.08 ( 0.44 )
    -5.00 ( 0.48 )
        DB Week 32 (n=13,10)
    -5.63 ( 0.18 )
    -5.55 ( 0.20 )
        DB Week 36 (n=13,10)
    -5.81 ( 0.18 )
    -5.87 ( 0.21 )
        DB Week 40 (n=11,9)
    -5.98 ( 0.16 )
    -5.94 ( 0.18 )
        DB Week 44 (n=10, 9)
    -5.95 ( 0.21 )
    -5.79 ( 0.23 )
        DB Week 48 (n=8, 5)
    -5.45 ( 0.31 )
    -5.30 ( 0.57 )
        DB Week 52 (n=6, 5)
    -6.06 ( 0.25 )
    -5.98 ( 0.43 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [291]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.66
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    1.49
    Notes
    [291] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [292]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.78
         upper limit
    1.1
    Notes
    [292] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [293]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.57
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.26
         upper limit
    1.41
    Notes
    [293] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [294]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.65
         upper limit
    1.27
    Notes
    [294] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [295]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.82
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.2
         upper limit
    1.85
    Notes
    [295] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [296]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.51
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.2
         upper limit
    2.22
    Notes
    [296] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [297]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.51
         upper limit
    1.22
    Notes
    [297] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [298]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.82
         upper limit
    0.5
    Notes
    [298] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [299]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.04
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.55
         upper limit
    0.47
    Notes
    [299] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [300]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.51
         upper limit
    0.63
    Notes
    [300] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [301]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.65
         upper limit
    0.5
    Notes
    [301] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [302]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.08
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.05
         upper limit
    0.88
    Notes
    [302] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [303]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.08
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.43
         upper limit
    1.27
    Notes
    [303] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Open-Label baseline value, and Open-Label baseline value by visit interaction.

    Secondary: Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [304]
    End point description
    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where ‘0’= Very Well’ and ‘10=Very Poorly. DBFAS set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [304] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4 (n=27,30)
    0.46 ( 0.28 )
    -0.03 ( 0.27 )
        DB Week 8 (n=25,25)
    0.60 ( 0.38 )
    0.12 ( 0.38 )
        DB Week 12 (n=21,23)
    0.25 ( 0.36 )
    0.22 ( 0.35 )
        DB Week 16 (n=21,20)
    0.27 ( 0.31 )
    0.04 ( 0.31 )
        DB Week 20 (n=19,15)
    0.14 ( 0.37 )
    0.05 ( 0.38 )
        DB Week 24 (n=18,15)
    0.14 ( 0.29 )
    -0.14 ( 0.30 )
        DB Week 28 (n=17,12)
    0.54 ( 0.52 )
    0.52 ( 0.56 )
        DB Week 32 (n=13,10)
    -0.32 ( 0.24 )
    -0.34 ( 0.25 )
        DB Week 36 (n=13,10)
    -0.56 ( 0.21 )
    -0.63 ( 0.22 )
        DB Week 40 (n=11,9)
    -0.72 ( 0.19 )
    -0.78 ( 0.20 )
        DB Week 44 (n=10,9)
    -0.65 ( 0.24 )
    -0.54 ( 0.25 )
        DB Week 48 (n=8,5)
    -0.16 ( 0.36 )
    -0.37 ( 0.53 )
        DB Week 52 (n=6,5)
    -0.82 ( 0.26 )
    -0.87 ( 0.38 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [305]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.32
         upper limit
    1.3
    Notes
    [305] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [306]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.48
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.64
         upper limit
    1.61
    Notes
    [306] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [307]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.02
         upper limit
    1.07
    Notes
    [307] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [308]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.69
         upper limit
    1.14
    Notes
    [308] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [309]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.05
         upper limit
    1.22
    Notes
    [309] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [310]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.28
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.6
         upper limit
    1.16
    Notes
    [310] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [311]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.6
         upper limit
    1.64
    Notes
    [311] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [312]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.58
         upper limit
    0.73
    Notes
    [312] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [313]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.6
         upper limit
    1.64
    Notes
    [313] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [314]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.53
         upper limit
    0.65
    Notes
    [314] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [315]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.13
         upper limit
    1.54
    Notes
    [315] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [316]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.87
         upper limit
    0.64
    Notes
    [316] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [317]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1
         upper limit
    1.11
    Notes
    [317] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-label Phase Part 1 [318]
    End point description
    The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4–6 response options.The CHQ score was determined based on the parent/legal guardian/adult caregiver’s questionnaire responses. OLPT1 analysis set was used. All participants reported under Number of subjects analysed” contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    OL Baseline up to 16 weeks
    Notes
    [318] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Global Health Subscale Standardized Score n=85
    26.12 ( 29.10 )
        Physical Functioning Standardized Score n=85
    28.95 ( 33.79 )
        Social Limitations: Emotional Score n=84
    27.51 ( 38.39 )
        Social Limitations: Physical Score n=84
    31.15 ( 42.96 )
        Bodily Pain Subscale Standardized Score n=85
    32.00 ( 26.67 )
        Behavior Subscale Standardized Score n=85
    10.98 ( 17.14 )
        Global Behavior Subscale Standardized Score n=85
    11.18 ( 27.75 )
        Mental Health Subscale Standardized Score n=84
    13.33 ( 20.20 )
        Self Esteem Subscale Standardized Score n=83
    7.68 ( 21.29 )
        General Health Subscale Score n=85
    8.37 ( 13.93 )
        Change in Health Subscale Score n=85
    1.28 ( 1.10 )
        Emotional Impact on Parent Subscale Score n=85
    12.75 ( 26.43 )
        Time Impact on Parent Standardized Score n=84
    14.81 ( 28.62 )
        Family Activities Standardized Score n=84
    74.03 ( 22.41 )
        Family Cohesion Standardized Score n=84
    8.10 ( 22.67 )
    No statistical analyses for this end point

    Secondary: Change From Open-Label Baseline in CHQ Responses at End of Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-Label Baseline in CHQ Responses at End of Open-label Phase Part 2 [319]
    End point description
    The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4–6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver’s questionnaire responses. OLPT2 analysis set was used. “Number of subjects analysed” =participants evaluable for the endpoint and “n” =number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) up to 24 weeks
    Notes
    [319] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    29
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Global Health Standardized Score n=29
    25.52 ( 35.46 )
        Physical Functioning Standardized Score n=29
    33.33 ( 31.29 )
        Social Limitations: Emotional Score n=28
    28.17 ( 43.98 )
        Social Limitations: Physical Score n=28
    38.10 ( 42.28 )
        Bodily Pain Standardized Score n=29
    34.48 ( 26.80 )
        Behavior Standardized Score n=29
    13.02 ( 21.14 )
        Global Behavior Standardized Score n=29
    10.00 ( 34.10 )
        Mental Health Standardized Score n=28
    18.04 ( 21.01 )
        Self Esteem Standardized Score n=27
    8.30 ( 34.18 )
        General Health Standardized Score n=28
    8.18 ( 15.94 )
        Change in Health Subscale Score n=28
    1.54 ( 1.23 )
        Emotional Impact on Parent Standardized Score n=28
    22.92 ( 36.33 )
        Time Impact on Parent Standardized Score n=27
    34.57 ( 25.66 )
        Family Activities Standardized Score n=27
    27.62 ( 25.87 )
        Family Cohesion Standardized Score n=27
    10.00 ( 23.25 )
    No statistical analyses for this end point

    Secondary: Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase [320]
    End point description
    The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4–6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver’s questionnaire responses. DBFAS analysis set was used. “Number of subjects analysed” =participants evaluable for the endpoint and “n” =number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    DB Baseline (values at randomization), DB Weeks 24, 48
    Notes
    [320] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    17
    15
    Units: Units on a scale
    least squares mean (standard error)
        Global Health Score:Week 24 n= (17,15)
    4.02 ( 4.71 )
    -1.98 ( 5.02 )
        Global Health Score:Week 48 n= (5,4)
    4.09 ( 3.93 )
    1.24 ( 4.49 )
        Physical Functioning Score:Week 24 n=(17,15)
    2.51 ( 3.86 )
    6.70 ( 3.99 )
        Physical Functioning Score:Week 48 n=(5,4)
    5.24 ( 9.13 )
    2.93 ( 14.02 )
        Social Limitation:Emotional Score:Week24 n=(17,15)
    2.62 ( 4.00 )
    8.09 ( 4.18 )
        Social Limitation:Emotional Score:Week48 n=(5,4)
    6.09 ( 7.69 )
    -0.73 ( 10.33 )
        Social Limitations:Physical Score:Week24 n=(17,15)
    2.75 ( 4.27 )
    8.98 ( 4.54 )
        Social Limitations:Physical Score:Week48 n=(5,4)
    3.45 ( 13.33 )
    -7.64 ( 20.06 )
        Bodily Pain Score:Week 24 n=(17,15)
    -1.61 ( 4.19 )
    -0.16 ( 4.41 )
        Bodily Pain Score:Week 48 n=(5,4)
    -2.72 ( 10.19 )
    -19.92 ( 13.98 )
        Behavior Score:Week 24 n=(17,15)
    2.33 ( 2.68 )
    7.48 ( 2.87 )
        Behavior Score:Week 48 n=(5,4)
    -4.50 ( 4.97 )
    10.53 ( 5.35 )
        Global Behavior Score:Week 24 n=(17,15)
    4.17 ( 3.89 )
    9.48 ( 4.13 )
        Global Behavior Score:Week48 n=(5,4)
    5.90 ( 4.00 )
    13.14 ( 4.54 )
        Mental Health Score:Week 24 n=(17,15)
    6.59 ( 3.56 )
    2.14 ( 3.78 )
        Mental Health Score:Week48 n=(5,4)
    0.79 ( 4.98 )
    8.26 ( 5.71 )
        Self Esteem Score:Week 24 n= (17,15)
    6.68 ( 3.05 )
    6.69 ( 3.24 )
        Self Esteem Score:Week 48 n=(5,4)
    3.05 ( 7.24 )
    10.64 ( 8.04 )
        General Health Score:Week 24 n=(17,15)
    5.02 ( 3.21 )
    0.03 ( 3.42 )
        General Health Score:Week 48 n=(5,4)
    9.59 ( 5.20 )
    10.60 ( 5.92 )
        Change in Health Score:Week 24 n=(17,15)
    0.45 ( 0.12 )
    0.48 ( 0.13 )
        Change in Health Score:Week48 n=(5,4)
    0.64 ( 0.32 )
    0.16 ( 0.35 )
        Emotional Impact on Parent Score:Week 24 n=(17,15)
    15.00 ( 4.28 )
    12.75 ( 4.53 )
        Emotional Impact on Parent Score:Week 48 n=(5,4)
    7.15 ( 10.25 )
    32.22 ( 11.79 )
        Time Impact on Parent Score Week 24 n=(17,15)
    7.53 ( 5.10 )
    5.66 ( 5.25 )
        Time Impact on Parent Score Week 48 n=(5,4)
    11.60 ( 8.94 )
    20.79 ( 14.05 )
        Family Activities Score:Week 24 n=(17,15)
    5.71 ( 2.96 )
    9.68 ( 3.13 )
        Family Activities Score:Week 48 n=(5,4)
    6.65 ( 5.73 )
    15.95 ( 7.16 )
        Family Cohesion Score:Week 24 n=(17,15)
    2.84 ( 3.71 )
    6.36 ( 3.96 )
        Family Cohesion Score:Week 48 n=(5,4)
    -12.24 ( 13.08 )
    8.18 ( 15.58 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Physical Subscale score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [321]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -6.22
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -18.95
         upper limit
    6.5
    Notes
    [321] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Emotional Subscale score:DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [322]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    6.82
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.92
         upper limit
    34.57
    Notes
    [322] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Emotional Subscale score:DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [323]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -5.47
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -17.37
         upper limit
    6.43
    Notes
    [323] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Physical Functioning Score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [324]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    2.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -37.06
         upper limit
    41.68
    Notes
    [324] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Physical Functioning Score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [325]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -4.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.78
         upper limit
    7.4
    Notes
    [325] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Global Health Score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [326]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    2.85
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.43
         upper limit
    18.14
    Notes
    [326] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Global Health Score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [327]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -8.35
         upper limit
    20.36
    Notes
    [327] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Global Behavior score:DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [328]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -7.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.35
         upper limit
    5.87
    Notes
    [328] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Global Behavior score:DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [329]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -5.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.92
         upper limit
    6.29
    Notes
    [329] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Behavior Subscale score:DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [330]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -15.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -33.12
         upper limit
    3.06
    Notes
    [330] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Behavior Subscale score:DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [331]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -5.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.24
         upper limit
    2.93
    Notes
    [331] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Bodily Pain Subscale score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [332]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    17.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -28.01
         upper limit
    62.41
    Notes
    [332] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Bodily Pain Subscale score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [333]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.97
         upper limit
    11.06
    Notes
    [333] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Physical Subscale score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [334]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    11.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -46.24
         upper limit
    68.42
    Notes
    [334] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Mental Health score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [335]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    4.44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -6.18
         upper limit
    15.07
    Notes
    [335] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    General Health Subscale score:DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [336]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    4.98
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.81
         upper limit
    14.77
    Notes
    [336] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Self Esteem Subscale score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [337]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -7.59
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -33.87
         upper limit
    18.7
    Notes
    [337] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Self Esteem Subscale score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [338]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -9.14
         upper limit
    9.13
    Notes
    [338] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Mental Health score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [339]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -7.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.37
         upper limit
    9.45
    Notes
    [339] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    General Health Subscale score:DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [340]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -1.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.31
         upper limit
    18.28
    Notes
    [340] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Health Subscale Score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [341]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.4
         upper limit
    0.33
    Notes
    [341] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Health Subscale Score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [342]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.48
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.68
         upper limit
    1.65
    Notes
    [342] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Emotional Impact on Parent Subscale score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [343]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    2.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -10.59
         upper limit
    15.1
    Notes
    [343] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Emotional Impact on Parent Subscale score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [344]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -25.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -60.96
         upper limit
    10.82
    Notes
    [344] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Family Cohesion Subscale Score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [345]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -20.42
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -79.03
         upper limit
    38.18
    Notes
    [345] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Family Cohesion Subscale Score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [346]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -3.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -14.84
         upper limit
    7.81
    Notes
    [346] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Family Activities Subscale Score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [347]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -9.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -32.35
         upper limit
    13.75
    Notes
    [347] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Family Activities Subscale Score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [348]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -3.97
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.84
         upper limit
    4.9
    Notes
    [348] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Time Impact on Parent Subscale score: DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [349]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -9.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -48.91
         upper limit
    30.53
    Notes
    [349] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    Time Impact on Parent Subscale score: DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    [350]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    1.87
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.55
         upper limit
    17.29
    Notes
    [350] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [351]
    End point description
    For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with ‘0’ as ‘No pain’ and ‘10’ as ‘Very severe pain’ on a 21-circle VAS. OLPT1 analysis set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, “n” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline ((last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Day 7, Weeks 2, 4, 8, 12, 16
    Notes
    [351] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 1 Day 7, n=99
    -1.20 ( 1.77 )
        Part 1 Week 2, n=98
    -1.87 ( 2.07 )
        Part 1 Week 4, n=97
    -2.57 ( 2.14 )
        Part 1 Week 8, n=82
    -3.30 ( 2.45 )
        Part 1 Week 12, n=44
    -3.57 ( 2.50 )
        Part 1 Week 16, n=24
    -3.69 ( 2.28 )
    No statistical analyses for this end point

    Secondary: Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [352]
    End point description
    For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with ‘0’ as ‘No pain’ and ‘10’ as ‘very severe pain’ on a 21-circle VAS. OLPT2 analysis set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here “Number Analysed” signifies number of participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [352] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Part 2 Week 4,n=50
    -4.23 ( 3.14 )
        Part 2 Week 8,n=40
    -4.38 ( 2.95 )
        Part 2 Week 12,n=31
    -4.42 ( 3.26 )
        Part 2 Week 16,n=23
    -4.48 ( 2.88 )
        Part 2 Week 20,n=13
    -5.15 ( 3.52 )
        Part 2 Week 24,n=3
    -6.00 ( 1.73 )
    No statistical analyses for this end point

    Secondary: Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [353]
    End point description
    For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with ‘0’ as ‘No pain’ and ‘10’ as ‘very severe pain’ on a 21-circle VAS. DBFAS consisted of all randomised participants who received at least one dose of investigational product in the double-blind phase. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [353] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Units on a scale
    least squares mean (standard error)
        DB Week 4(n=27,30)
    0.13 ( 0.28 )
    0.37 ( 0.26 )
        DB Week 8 (n=25,25)
    0.56 ( 0.36 )
    0.02 ( 0.35 )
        DB Week 12(n=21,23)
    0.04 ( 0.34 )
    0.09 ( 0.32 )
        DB Week 16 (n=21,20)
    0.44 ( 0.36 )
    -0.11 ( 0.35 )
        DB Week 20 (n=19,15)
    0.09 ( 0.40 )
    -0.14 ( 0.42 )
        DB Week 24 (n=18,15)
    0.07 ( 0.27 )
    -0.25 ( 0.28 )
        DB Week 28 (n=17,12)
    -0.03 ( 0.47 )
    0.39 ( 0.51 )
        DB Week 32(n=13,10)
    -0.31 ( 0.39 )
    0.01 ( 0.42 )
        DB Week 36(n=13,10)
    -0.55 ( 0.34 )
    -0.24 ( 0.37 )
        DB Week 40(n=11,9)
    -0.76 ( 0.20 )
    -0.83 ( 0.21 )
        DB Week 44 (n=10, 9)
    -1.09 ( 0.23 )
    -0.79 ( 0.24 )
        DB Week 48 (n=8, 5)
    -0.19 ( 0.49 )
    -0.43 ( 0.79 )
        DB Week 52 (n=6, 5)
    -0.85 ( 0.21 )
    -0.76 ( 0.34 )
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [354]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.02
         upper limit
    0.54
    Notes
    [354] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [355]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.47
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.01
         upper limit
    0.9
    Notes
    [355] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [356]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.55
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.49
         upper limit
    1.58
    Notes
    [356] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [357]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.98
         upper limit
    1.45
    Notes
    [357] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [358]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.51
         upper limit
    1.14
    Notes
    [358] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [359]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.87
         upper limit
    0.69
    Notes
    [359] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [360]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.53
         upper limit
    0.88
    Notes
    [360] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [361]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.36
         upper limit
    0.74
    Notes
    [361] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [362]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.55
         upper limit
    0.69
    Notes
    [362] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [363]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.31
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.01
         upper limit
    0.39
    Notes
    [363] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [364]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.45
         upper limit
    1.92
    Notes
    [364] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [365]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.54
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.49
         upper limit
    1.57
    Notes
    [365] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [366]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    -0.42
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.87
         upper limit
    1.03
    Notes
    [366] - Analysis performed using MMRM which included the fixed effect of treatment, visit, treatment by visit interaction, Double-Blind baseline value, and Double-Blind baseline value by visit interaction.

    Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 [367]
    End point description
    Minimal disease activity is defined as follows: Polyarthritis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. OLPT1 analysis set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
    Notes
    [367] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 1 Day 7; n=97
    3.09 (0 to 6.54)
        Part 1 Week 2; n=96
    5.21 (0.76 to 9.65)
        Part 1 Week 4; n=97
    6.19 (1.39 to 10.98)
        Part 1 Week 8; n=80
    13.75 (6.20 to 21.30)
        Part 1 Week 12; n=44
    13.64 (3.50 to 23.78)
        Part 1 Week 16; n=24
    25.00 (7.68 to 42.32)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 [368]
    End point description
    Minimal disease activity is defined as follows: Polyarthritis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. OLPT1 analysis set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
    Notes
    [368] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 1 Day 7: n=98
    1.02 (0 to 3.01)
        Part 1 Week 2: n=98
    4.08 (0.16 to 8.00)
        Part 1 Week 4: n=97
    7.22 (2.07 to 12.37)
        Part 1 Week 8: n=81
    14.81 (7.08 to 22.55)
        Part 1 Week 12: n=44
    15.91 (5.10 to 26.72)
        Part 1 Week 16: n=24
    20.83 (4.59 to 37.08)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [369]
    End point description
    Minimal disease activity is defined as follows: Polyarthritis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. OLPT2 analysis set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [369] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 2 Week 4; n=50
    36.00 (22.70 to 49.30)
        Part 2 Week 8; n=40
    30.00 (15.80 to 44.20)
        Part 2 Week 12; n=31
    32.26 (15.80 to 48.71)
        Part 2 Week 16; n=22
    36.36 (16.26 to 56.47)
        Part 2 Week 20; n=13
    53.85 (26.75 to 80.95)
        Part 2 Week 24; n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 [370]
    End point description
    Inactive Disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT1 set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
    Notes
    [370] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of Participants
    number (confidence interval 95%)
        Part 1 Day 7; n=97
    0 (0 to 0)
        Part 1 Week 2; n=96
    3.13 (0 to 6.61)
        Part 1 Week 4; n=97
    3.09 (0 to 6.54)
        Part 1 Week 8; n=80
    5.00 (0.22 to 9.78)
        Part 1 Week 12; n=44
    4.55 (0 to 10.70)
        Part 1 Week 16; n=24
    4.17 (0 to 12.16)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [371]
    End point description
    Minimal disease activity is defined as follows: Polyarthritis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. OLPT2 analysis set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [371] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 2 Week 4; n=50
    32.00 (19.07 to 44.93)
        Part 2 Week 8; n=40
    27.50 (13.66 to 41.34)
        Part 2 Week 12; n=31
    29.03 (13.05 to 45.01)
        Part 2 Week 16; n=23
    34.78 (15.32 to 54.25)
        Part 2 Week 20; n=13
    53.85 (26.75 to 80.95)
        Part 2 Week 24; n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1 [372]
    End point description
    Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT1 set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
    Notes
    [372] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of Participants
    number (confidence interval 95%)
        Part 1 Day 7; n=98
    0 (0 to 0)
        Part 1 Week 2; n=98
    2.04 (0 to 4.84)
        Part 1 Week 4; n=97
    1.03 (0 to 3.04)
        Part 1 Week 8; n=81
    3.70 (0 to 7.82)
        Part 1 Week 12; n=44
    6.82 (0 to 14.27)
        Part 1 Week 16; n=24
    4.17 (0 to 12.16)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [373]
    End point description
    Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT2 set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [373] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of Participants
    number (confidence interval 95%)
        Part 2 Week 4; n=50
    16.00 (5.84 to 26.16)
        Part 2 Week 8; n=40
    20.00 (7.60 to 32.40)
        Part 2 Week 12; n=31
    9.68 (0 to 20.09)
        Part 2 Week 16; n=22
    18.18 (2.06 to 34.30)
        Part 2 Week 20; n=13
    38.46 (12.01 to 64.91)
        Part 2 Week 24; n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [374]
    End point description
    Inactive Disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. OLPT2 set was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. Here, n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [374] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of Participants
    number (confidence interval 95%)
        Part 2 Week 4; n=50
    16.00 (5.84 to 26.16)
        Part 2 Week 8; n=40
    17.50 (5.72 to 29.28)
        Part 2 Week 12; n=31
    9.68 (0 to 20.09)
        Part 2 Week 16; n=23
    17.39 (1.90 to 32.88)
        Part 2 Week 20; n=13
    46.15 (19.05 to 73.25)
        Part 2 Week 24; n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [375]
    End point description
    Minimal disease activity is defined as follows: Polyarthritis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. DBFAS analysis set was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
    Notes
    [375] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of Participants
    number (not applicable)
        DB Week 4
    21.43
    51.61
        DB Week 8
    25.00
    48.39
        DB Week 12
    32.14
    32.26
        DB Week 16
    35.71
    29.03
        DB Week 20
    35.71
    22.58
        DB Week 24
    35.71
    35.48
        DB Week 28
    35.71
    32.26
        DB Week 32
    28.57
    22.58
        DB Week 36
    39.29
    35.48
        DB Week 40
    39.29
    29.03
        DB Week 44
    46.43
    25.81
        DB Week 48
    46.43
    25.81
        DB Week 52
    46.43
    29.03
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [376]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -0.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -23.99
         upper limit
    23.76
    Notes
    [376] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [377]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -23.39
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -47.19
         upper limit
    0.42
    Notes
    [377] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [378]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -30.18
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -53.43
         upper limit
    -6.94
    Notes
    [378] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [379]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    17.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -7.03
         upper limit
    41.82
    Notes
    [379] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [380]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    5.99
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.29
         upper limit
    28.28
    Notes
    [380] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [381]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    3.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.92
         upper limit
    28.52
    Notes
    [381] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [382]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    10.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.88
         upper limit
    34.39
    Notes
    [382] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [383]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    20.62
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.43
         upper limit
    44.67
    Notes
    [383] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [384]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    20.62
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.43
         upper limit
    44.67
    Notes
    [384] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [385]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.24
         upper limit
    24.7
    Notes
    [385] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [386]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    13.13
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -9.92
         upper limit
    36.19
    Notes
    [386] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [387]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    6.68
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -17.2
         upper limit
    30.56
    Notes
    [387] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [388]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    3.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.75
         upper limit
    27.66
    Notes
    [388] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Secondary: Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [389]
    End point description
    Minimal disease activity is defined as follows: Polyarthritis (>4 active joints): Minimal Disease Activity: less than equal (<=) 3.8. Oligoarthritis (<= 4 active joints): Minimal Disease Activity: <=2. DBFAS analysis set was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
    Notes
    [389] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of Participants
    number (not applicable)
        DB Week 4
    25.00
    51.61
        DB Week 8
    25.00
    45.16
        DB Week 12
    32.14
    41.94
        DB Week 16
    35.71
    35.48
        DB Week 20
    39.29
    29.03
        DB Week 24
    35.71
    38.71
        DB Week 28
    35.71
    38.71
        DB Week 32
    28.57
    35.48
        DB Week 36
    39.29
    35.48
        DB Week 40
    39.29
    32.26
        DB Week 44
    50.00
    32.26
        DB Week 48
    50.00
    35.48
        DB Week 52
    50.00
    32.26
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [390]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -26.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -50.42
         upper limit
    -2.81
    Notes
    [390] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [391]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -20.16
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -43.91
         upper limit
    3.59
    Notes
    [391] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [392]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -9.79
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -34.31
         upper limit
    14.72
    Notes
    [392] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [393]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.23
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.24
         upper limit
    24.7
    Notes
    [393] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [394]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    10.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.88
         upper limit
    34.39
    Notes
    [394] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [395]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.67
         upper limit
    21.68
    Notes
    [395] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [396]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.67
         upper limit
    21.68
    Notes
    [396] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [397]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -6.91
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -30.65
         upper limit
    16.83
    Notes
    [397] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [398]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    3.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.92
         upper limit
    28.52
    Notes
    [398] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [399]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    7.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -17.43
         upper limit
    31.48
    Notes
    [399] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [400]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    17.74
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -7.03
         upper limit
    42.52
    Notes
    [400] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [401]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    14.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -10.52
         upper limit
    39.55
    Notes
    [401] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [402]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    17.74
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -7.03
         upper limit
    42.52
    Notes
    [402] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [403]
    End point description
    Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. DBFAS set was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
    Notes
    [403] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of Participants
    number (not applicable)
        DB Week 4
    10.71
    25.81
        DB Week 8
    7.14
    19.35
        DB Week 12
    7.14
    16.13
        DB Week 16
    14.29
    9.68
        DB Week 20
    14.29
    9.68
        DB Week 24
    7.14
    16.13
        DB Week 28
    10.71
    22.58
        DB Week 32
    14.29
    19.35
        DB Week 36
    10.71
    16.13
        DB Week 40
    14.29
    25.81
        DB Week 44
    14.29
    16.13
        DB Week 48
    10.71
    19.35
        DB Week 52
    14.29
    19.35
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [404]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -15.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -34.29
         upper limit
    4.1
    Notes
    [404] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [405]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.99
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.07
         upper limit
    7.1
    Notes
    [405] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [406]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    4.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.01
         upper limit
    21.23
    Notes
    [406] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [407]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    4.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.01
         upper limit
    21.23
    Notes
    [407] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [408]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.99
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.07
         upper limit
    7.1
    Notes
    [408] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [409]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -12.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -29.08
         upper limit
    4.65
    Notes
    [409] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [410]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.87
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -30.52
         upper limit
    6.79
    Notes
    [410] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [411]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -5.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.08
         upper limit
    13.94
    Notes
    [411] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [412]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -5.41
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -22.7
         upper limit
    11.87
    Notes
    [412] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [413]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -31.65
         upper limit
    8.61
    Notes
    [413] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [414]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -1.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.16
         upper limit
    16.48
    Notes
    [414] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [415]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.66
         upper limit
    9.38
    Notes
    [415] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [416]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -5.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.08
         upper limit
    13.94
    Notes
    [416] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Secondary: Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [417]
    End point description
    Inactive disease activity is defined as based on JADAS 27 score follows: Polyarthritis (>4 active joints): Inactive Disease: (<=1; Oligoarthritis (<= 4 active joints): Inactive Disease: (<=1. DBFAS set was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
    Notes
    [417] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of Participants
    number (not applicable)
        DB Week 4
    7.14
    19.35
        DB Week 8
    14.29
    29.03
        DB Week 12
    14.29
    22.58
        DB Week 16
    17.86
    16.13
        DB Week 20
    14.29
    12.90
        DB Week 24
    10.71
    16.13
        DB Week 28
    10.71
    22.58
        DB Week 32
    14.29
    19.35
        DB Week 36
    10.71
    19.35
        DB Week 40
    14.29
    25.81
        DB Week 44
    14.29
    22.58
        DB Week 48
    14.29
    22.58
        DB Week 52
    14.29
    19.35
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [418]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -14.75
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -35.32
         upper limit
    5.83
    Notes
    [418] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 4
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [419]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -12.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -29.08
         upper limit
    4.65
    Notes
    [419] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 12
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [420]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.91
         upper limit
    11.32
    Notes
    [420] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [421]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.87
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -30.52
         upper limit
    6.79
    Notes
    [421] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [422]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -5.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.08
         upper limit
    13.94
    Notes
    [422] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [423]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.66
         upper limit
    9.38
    Notes
    [423] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [424]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.91
         upper limit
    11.32
    Notes
    [424] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [425]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.91
         upper limit
    11.32
    Notes
    [425] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [426]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -5.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -24.08
         upper limit
    13.94
    Notes
    [426] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [427]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -5.41
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -22.7
         upper limit
    11.87
    Notes
    [427] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 20
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [428]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    1.38
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -16.15
         upper limit
    18.91
    Notes
    [428] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 16
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [429]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    1.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -17.48
         upper limit
    20.93
    Notes
    [429] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [430]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -11.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -31.65
         upper limit
    8.61
    Notes
    [430] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Secondary: Percentage of Participants with JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Close Top of page
    End point title
    Percentage of Participants with JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1 [431]
    End point description
    The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of ‘best possible’ on the scale used; duration of morning stiffness of <=15 minutes. 95% CI was based on normal approximation. OLPT1 set was used. n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Baseline ((last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16
    Notes
    [431] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID Open_Label (OL) Part 1
    Number of subjects analysed
    100
    Units: Percentage of Participants
    number (confidence interval 95%)
        Baseline; n=100
    0 (0 to 0)
        Part 1 Day 3; n=96
    0 (0 to 0)
        Part 1 Day 7; n=99
    0 (0 to 0)
        Part 1 Week 2; n=99
    2.02 (0 to 4.79)
        Part 1 Week 4; n=97
    3.09 (0 to 6.54)
        Part 1 Week 8; n=83
    4.82 (0.21 to 9.43)
        Part 1 Week 12; n=44
    4.55 (0 to 10.70)
        Part 1 Week 16; n=24
    4.17 (0 to 12.16)
    No statistical analyses for this end point

    Secondary: Percentage of Participants with JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Close Top of page
    End point title
    Percentage of Participants with JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2 [432]
    End point description
    The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of ‘best possible’ on the scale used; duration of morning stiffness of <=15 minutes. 95% CI was based on normal approximation. OLPT2 was used. All participants reported under ‘Number of Participants Analysed’ contributed data to the table; however, may not have evaluable data for every row. n=number of participants evaluable for the specified time points and used for calculating percentages.
    End point type
    Secondary
    End point timeframe
    Part 2 Weeks 4, 8, 12, 16, 20, 24
    Notes
    [432] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Open-Label period hence Open-Label arms have been reported.
    End point values
    Tofacitinib 5mg BID OL Part 2
    Number of subjects analysed
    54
    Units: Percentage of participants
    number (confidence interval 95%)
        Part 2 Week 4;n=50
    14.00 (4.38 to 23.62)
        Part 2 Week 8;n=39
    10.26 (0.73 to 19.78)
        Part 2 Week 12;n=31
    6.45 (0 to 15.10)
        Part 2 Week 16;n=23
    13.04 (0 to 26.81)
        Part 2 Week 20;n=13
    15.38 (0 to 35.00)
        Part 2 Week 24;n=3
    33.33 (0 to 86.68)
    No statistical analyses for this end point

    Secondary: Percentage of Participants with JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Percentage of Participants with JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [433]
    End point description
    The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of ‘best possible’ on the scale used; duration of morning stiffness of <=15 minutes. 95% CI was based on normal approximation. DBFAS was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
    Notes
    [433] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of Participants
    number (not applicable)
        DB Week 4
    7.14
    16.13
        DB Week 8
    3.57
    22.58
        DB Week 12
    7.14
    22.58
        DB Week 16
    3.57
    16.13
        DB Week 20
    7.14
    16.13
        DB Week 24
    7.14
    19.35
        DB Week 28
    10.71
    19.35
        DB Week 32
    10.71
    19.35
        DB Week 36
    14.29
    16.13
        DB Week 40
    17.86
    22.58
        DB Week 44
    14.29
    22.58
        DB Week 48
    17.86
    22.58
        DB Week 52
    21.43
    19.35
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [434]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -15.44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -32.98
         upper limit
    2.1
    Notes
    [434] - DB Week 12
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 8
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [435]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -19.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -35.25
         upper limit
    -2.76
    Notes
    [435] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [436]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.99
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.07
         upper limit
    7.1
    Notes
    [436] - DB Week 4
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [437]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    2.07
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -18.53
         upper limit
    22.68
    Notes
    [437] - DB Week 52
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [438]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.66
         upper limit
    9.38
    Notes
    [438] - DB Week 32
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [439]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -1.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -20.16
         upper limit
    16.48
    Notes
    [439] - DB Week 36
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [440]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -4.72
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.17
         upper limit
    15.72
    Notes
    [440] - DB Week 40
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [441]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.91
         upper limit
    11.32
    Notes
    [441] - DB Week 44
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [442]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -4.72
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.17
         upper limit
    15.72
    Notes
    [442] - DB Week 48
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [443]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -12.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -29.08
         upper limit
    4.65
    Notes
    [443] - DB Week 24
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [444]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.99
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -25.07
         upper limit
    7.1
    Notes
    [444] - DB Week 20
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [445]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -12.56
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -27.22
         upper limit
    2.1
    Notes
    [445] - DB Week 16
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    other [446]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -8.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -26.66
         upper limit
    9.38
    Notes
    [446] - DB Week 28

    Secondary: Percentage of Participants with JIA ACR Clinical Remission at DB Weeks 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    Close Top of page
    End point title
    Percentage of Participants with JIA ACR Clinical Remission at DB Weeks 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase [447]
    End point description
    According to ACR, clinical remission was defined as clinical inactive disease for 24 weeks continuously while on medications. DBFAS was used. Missing response was imputed as non-response.
    End point type
    Secondary
    End point timeframe
    DB Weeks 24, 28, 32, 36, 40, 44, 48, 52
    Notes
    [447] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is specific to Double-Blind period hence Double-Blind arms have been reported.
    End point values
    Tofacitinib 5mg BID Double-Blind (DB) Placebo DB
    Number of subjects analysed
    28
    31
    Units: Percentage of participants
    number (not applicable)
        DB Week 24
    0
    3.23
        DB Week 28
    0
    3.23
        DB Week 32
    0
    3.23
        DB Week 36
    3.57
    3.23
        DB Week 40
    3.57
    3.23
        DB Week 44
    3.57
    6.45
        DB Week 48
    3.57
    9.68
        DB Week 52
    3.57
    9.68
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 24
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [448]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -2.96
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -11.69
         upper limit
    5.76
    Notes
    [448] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 32
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [449]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -2.96
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -11.69
         upper limit
    5.76
    Notes
    [449] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 28
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [450]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -2.96
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -11.69
         upper limit
    5.76
    Notes
    [450] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 48
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [451]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -6.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -18.58
         upper limit
    6.37
    Notes
    [451] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 44
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [452]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    -2.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -13.93
         upper limit
    8.17
    Notes
    [452] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 40
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [453]
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0.35
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -8.92
         upper limit
    9.62
    Notes
    [453] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 52
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [454]
    Method
    Mixed Model for Repeated Measures
    Parameter type
    Difference in percentage
    Point estimate
    -6.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -18.58
         upper limit
    6.37
    Notes
    [454] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
    Statistical analysis title
    Tofacitinib 5mg BID DB and Placebo DB
    Statistical analysis description
    DB Week 36
    Comparison groups
    Tofacitinib 5mg BID Double-Blind (DB) v Placebo DB
    Number of subjects included in analysis
    59
    Analysis specification
    Pre-specified
    Analysis type
    [455]
    Method
    Parameter type
    Difference in LS Mean
    Point estimate
    0.35
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -8.92
         upper limit
    9.62
    Notes
    [455] - The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From dose 1 up to 28 days after end of study treatment (maximum duration up to 16 weeks) for OL1 and for OL2 (maximum duration up to 24 weeks), For DB (maximum duration up to 248 weeks)
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    v26.1
    Reporting groups
    Reporting group title
    Tofacitinib 5mg BID OL Part 1
    Reporting group description
    Participants were administered tofacitinib 5 mg BID via the oral route and continued to receive a stable dose of corticosteroids during open label part 1.

    Reporting group title
    Tofacitinib 5mg BID OL Part 2
    Reporting group description
    Participants who achieved sJIA American college of rheumatology (ACR) 50 response and maintained sJIA ACR 30 response for 4 weeks were administered tofacitinib 5 mg BID and tapering dose of CSs for participants treated with ˃0.2 mg/kg/day oral prednisone (or equivalent).

    Reporting group title
    Tofacitinib 5mg BID DB
    Reporting group description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase continued to receive tofacitinib 5 mg BID orally during the double-blind withdrawal phase of the study.

    Reporting group title
    Placebo DB
    Reporting group description
    Participants who maintained a stable tapered CS dose for 4 weeks and maintained sJIA ACR 30 for 4 weeks from Part 1 and Part 2 of the open-label phase were randomised to receive placebo BID orally during the double-blind withdrawal phase of the study.

    Serious adverse events
    Tofacitinib 5mg BID OL Part 1 Tofacitinib 5mg BID OL Part 2 Tofacitinib 5mg BID DB Placebo DB
    Total subjects affected by serious adverse events
         subjects affected / exposed
    7 / 100 (7.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    2 / 31 (6.45%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Histiocytic necrotising lymphadenitis
         subjects affected / exposed
    1 / 100 (1.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hodgkin's disease
         subjects affected / exposed
    1 / 100 (1.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Overdose
         subjects affected / exposed
    1 / 100 (1.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Haemophagocytic lymphohistiocytosis
         subjects affected / exposed
    1 / 100 (1.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 100 (1.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Still's disease
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    Tofacitinib 5mg BID OL Part 1 Tofacitinib 5mg BID OL Part 2 Tofacitinib 5mg BID DB Placebo DB
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    33 / 100 (33.00%)
    15 / 54 (27.78%)
    23 / 28 (82.14%)
    25 / 31 (80.65%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Skin papilloma
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    6 / 100 (6.00%)
    2 / 54 (3.70%)
    4 / 28 (14.29%)
    1 / 31 (3.23%)
         occurrences all number
    6
    8
    9
    1
    Feeling cold
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Condition aggravated
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    3
    0
    1
    0
    Nasal obstruction
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Upper-airway cough syndrome
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    2
    Oropharyngeal pain
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Restlessness
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    1
    1
    Blood urine present
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Eosinophil count increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Haemoglobin decreased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    2 / 28 (7.14%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    2
    0
    Hepatic enzyme increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Red blood cell count increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Monocyte count increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Mean cell volume increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Transaminases increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    White blood cell count increased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    White blood cells urine positive
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Injury, poisoning and procedural complications
    Tibia fracture
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Skin laceration
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Skin abrasion
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Radius fracture
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Limb injury
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Ligament sprain
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Fall
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    2 / 28 (7.14%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    2
    0
    Contusion
         subjects affected / exposed
    0 / 100 (0.00%)
    2 / 54 (3.70%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    2
    1
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    1
    10
    Febrile convulsion
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Neutropenia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    2
    Thrombocytosis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Eye disorders
    Refraction disorder
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    3 / 28 (10.71%)
    1 / 31 (3.23%)
         occurrences all number
    3
    0
    6
    1
    Nausea
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    0 / 31 (0.00%)
         occurrences all number
    4
    0
    0
    0
    Abdominal pain
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 100 (0.00%)
    2 / 54 (3.70%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    2
    0
    1
    Diarrhoea
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    2 / 31 (6.45%)
         occurrences all number
    0
    0
    1
    3
    Gingival swelling
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Toothache
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Hepatobiliary disorders
    Hypertransaminasaemia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    2 / 28 (7.14%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    2
    0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    3
    0
    0
    1
    Erythema nodosum
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    1
    7
    Back pain
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Groin pain
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    2
    Joint range of motion decreased
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Joint swelling
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    2
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Myalgia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    0
    0
    2
    Pain in extremity
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    4
    Still's disease
         subjects affected / exposed
    0 / 100 (0.00%)
    3 / 54 (5.56%)
    8 / 28 (28.57%)
    14 / 31 (45.16%)
         occurrences all number
    0
    4
    8
    14
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    3 / 31 (9.68%)
         occurrences all number
    3
    0
    0
    3
    Upper respiratory tract infection
         subjects affected / exposed
    10 / 100 (10.00%)
    7 / 54 (12.96%)
    3 / 28 (10.71%)
    5 / 31 (16.13%)
         occurrences all number
    11
    11
    11
    19
    Nasopharyngitis
         subjects affected / exposed
    6 / 100 (6.00%)
    0 / 54 (0.00%)
    2 / 28 (7.14%)
    1 / 31 (3.23%)
         occurrences all number
    8
    0
    2
    1
    Influenza
         subjects affected / exposed
    3 / 100 (3.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    3
    0
    0
    1
    Acarodermatitis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Roseola
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Respiratory tract infection viral
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    2
    Respiratory tract infection
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Pyoderma
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Pneumonia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Pilonidal disease
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Pharyngotonsillitis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Pharyngitis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    0
    0
    2
    Mycoplasma infection
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Herpangina
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Gastroenteritis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    COVID-19
         subjects affected / exposed
    0 / 100 (0.00%)
    5 / 54 (9.26%)
    0 / 28 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    5
    0
    2
    Bronchitis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    0
    0
    2
    Acute sinusitis
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Tonsillitis bacterial
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    0 / 28 (0.00%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    0
    1
    Metabolism and nutrition disorders
    Hypercholesterolaemia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    1 / 31 (3.23%)
         occurrences all number
    0
    0
    1
    1
    Hypertriglyceridaemia
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    2 / 28 (7.14%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    3
    0
    Iron deficiency
         subjects affected / exposed
    0 / 100 (0.00%)
    0 / 54 (0.00%)
    1 / 28 (3.57%)
    0 / 31 (0.00%)
         occurrences all number
    0
    0
    2
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    16 May 2019
    Tofacitinib 10 mg BID dose will no longer be evaluated. References to the 10mg BID group and 10 mg BID dose increase at Day 14 are removed throughout the protocol.
    17 Mar 2021
    Participants who received previous JIA treatment with tofacitinib, baricitinib or any other JAK-inhibitor were excluded. This exclusion criterion was broadened to include any JAK-inhibitor.
    21 Jul 2021
    This global amendment incorporated updates to facilitate enrollment of sJIA participants who were previously treated with biological DMARDs or JAK-inhibitors.
    09 Feb 2022
    Discussion of the risks and benefits of using tofacitinib in the pediatric population added to the body of the protocol at the request of an ethics committee.
    01 Sep 2023
    This global amendment incorporated measures to further facilitate the interpretation of trial results. This included a modification to the statistical analysis. Additionally, editorial and typographic changes.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:51:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA